Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 20355. Отображено 100.
26-01-2012 дата публикации

Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System

Номер: US20120020915A1

Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Подробнее
09-02-2012 дата публикации

Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

Номер: US20120035230A1
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
23-02-2012 дата публикации

3-substituted propanamine compounds

Номер: US20120046312A1
Принадлежит: SK Biopharmaceuticals Co Ltd

Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.

Подробнее
29-03-2012 дата публикации

Pharmaceutical product

Номер: US20120077856A1
Принадлежит: Takeda Pharmaceutical Co Ltd

An agent for suppressing the production of various cytokines (IL-8 and the like) and inflammatory mediators, an agent for suppressing the expression of COX-II and the like, or an inhibitor of various phosphorylation enzymes (ATF2 and the like), which contains a TLR signaling inhibitory substance, preferably a compound represented by the formula (I) or the formula (II) wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

Подробнее
12-04-2012 дата публикации

Five-membered heterocycles useful as serine protease inhibitors

Номер: US20120088758A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Подробнее
26-04-2012 дата публикации

Click chemistry on heterogeneous catalysts

Номер: US20120100633A1
Принадлежит: BASECLICK GMBH

The present invention relates to new methods and reagents for coupling molecules by a Click reaction using a heterogeneous catalyst system. Further, the present invention refers to novel devices for carrying out Click reactions

Подробнее
17-05-2012 дата публикации

Compounds, Compositions and Methods for Modulating Uric Acid Levels

Номер: US20120122780A1
Принадлежит: Ardea Biociences Inc

Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Подробнее
24-05-2012 дата публикации

Triterpenoid derivatives useful as antiproliferative agents

Номер: US20120129901A1
Принадлежит: Individual

Formula (I) and (II). The present invention relates to the use of a new lupane derivative of general formula (I) or (II), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, for preventing and/or inhibiting tumor growth and for treating cancer and other proliferative diseases, more particularly for treating leukemia, liver, cervical, colon and prostate cancer. The present invention also relates to the synthesis of these compounds and to pharmaceutical compositions which contain them.

Подробнее
31-05-2012 дата публикации

Substituted Esters as Cannabinoid-1 Receptor Modulators

Номер: US20120135975A1
Принадлежит: Merck and Co Inc

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

Подробнее
09-08-2012 дата публикации

Pesticidal compositions and processes related thereto

Номер: US20120202688A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses pesticidal compostions comprising molecules having the following formulas: and processes related thereto.

Подробнее
09-08-2012 дата публикации

Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Номер: US20120202760A1
Автор: Rashida A. Karmali
Принадлежит: Individual

This invention relates to enhancing sensitivity of cytotoxic drugs by targeting their interfering mechanisms induced in the tumor microenvironment which lead to drug resistance, using combinatorial therapy with carboxyamidotriazole orotate. Specific doses of cytotoxic drugs are titrated with carboxyamidotriazole orotate to improve the sensitivity and anticancer activity of cytotoxic drugs.

Подробнее
09-08-2012 дата публикации

Polymorphic forms of deferasirox (icl670a)

Номер: US20120203007A1
Автор: Michael Mutz
Принадлежит: NOVARTIS AG

The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
20-09-2012 дата публикации

Iodine radiolabelling method

Номер: US20120237444A1
Автор: Michelle Avory
Принадлежит: Individual

The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using the radioiodinated BTMs.

Подробнее
04-10-2012 дата публикации

Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies

Номер: US20120252858A1
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
07-02-2013 дата публикации

Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making

Номер: US20130035394A1
Принадлежит: University of Minnesota

A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.

Подробнее
14-02-2013 дата публикации

Electroluminescent materials comprising fluorene derivatives

Номер: US20130037752A1
Автор: Gene Carl Koch
Принадлежит: Lomox Ltd

OLED compounds of the general structure: B—S-A-S—B in which rod-like nuclei A includes a condensed aromatic ring structure in turn having fluorene ring structures condensed with at least one additional fluorene ring structures wherein the fluorene ring systems provided by the condensed aromatic structure are substituted at the 9-position, and in which the 9-positions of the fluorenes are not susceptible to oxidation.

Подробнее
28-02-2013 дата публикации

Diazeniumdiolate cyclopentyl derivatives

Номер: US20130053352A1
Принадлежит: Merck Sharp and Dohme LLC

A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, —OH, —O—C 1-6 alkyl, ═O, or halogen; R 2 is hydrogen, C(O)OR 8 , C 6 H 5 C(O)OR 8 , (CH 2 ) 1-2 OH, CR 9 R 10 OH, C(O)O(CH 2 ) 0-2 aryl, C(O)NR 9 R 10 , C(O)SO 2 NR 9 R 10 , C 6 H 5 OR 9 , W—C(O)OR 8 , W—OR 9 , Y, or P(O)(OR 9 )(ORlO); R 3 is hydrogen or —C 1-6 alkyl; R 4 is hydrogen, —OH or —C(O)OR 9 ; R 5 is hydrogen or deuterium; R 6 and R 7 are independently —C 1-6 alkyl, fluoro-substituted —C 1-6 alkyl, deutero-substituted —C 1-6 alkyl or —(CH 2 ) 1-2 R 11 , wherein any carbon atom of the fluoro-substituted —C 1-6 alkyl is mono- or di-substituted with fluoro, and any carbon atom of the deutero-substituted —C 1-6 alkyl is mono- or di-substituted with fluoro; R 8 , in each instance in which it occurs, is independently hydrogen, —C 1-6 alkyl, or —(CH 2 ) 2 N + (CH 3 ) 3 ; R 9 and R 10 , in each instance in which they occur, are independently —C 1-6 alkyl; R 11 is —OH, —O—C 1-6 alkyl, -0CD3, —OC(O)OC 1-6 alkyl, —NH 2 , —C 6 H 5 , —N 3 , or W; W is an unsubslituted 5- or 6-raembered heteroaryl ring having 1, 2, or 3 nitrogen atoms, or a substituted 5- or 6-membered heteroaryl ring having 1, 2, or 3 nitrogen atoms that is mono- or di-substituted at any carbon atom with R 6 or R 7 ; Y is a 5- or 6-membered heterocyclic ring having 1, 2, 3 or 4 heteroatoms which are N, O, or S or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or pharmaceutically acceptable salts of stereoisomers thereof, and methods of using the compounds for treating hypertension.

Подробнее
18-04-2013 дата публикации

COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS

Номер: US20130096165A1
Принадлежит: IRM LLC

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120. 2. (canceled)3. The compound of claim 1 , wherein Ris H or Calkyl.4. The compound of claim 3 , wherein each Ris independently a halo.5. The compound of claim 4 , wherein each Ris independently selected from fluoro and bromo.6. (canceled)8. The compound of selected from:3-(4-p-tolyl-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(2,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)benzoic acid,3-(1-(4-isopropylphenyl)-1H-1,2,3-triazol-4-yl)benzoic acid,3-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)-5-methoxybenzoic acid,3-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)-5-fluorobenzoic acid,3-(1-(2-fluoro-4-methylphenyl)-1H-1,2,3-triazol-4-yl)benzoic acid,5-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)-2-fluorobenzoic acid and3-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)-4-fluorobenzoic acid.9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) of claim 1 , and a pharmaceutically acceptable carrier.10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. A method for treating a disease or disorder where modulation of GPR120 is implicated claim 1 , comprising administering to a system or subject in need of such treatment an effective amount of a compound of Formula (I) of claim 1 , or pharmaceutically acceptable salts or pharmaceutical compositions thereof claim 1 , thereby treating the disease or disorder claim 1 , wherein the disease or disorder is selected ...

Подробнее
25-04-2013 дата публикации

Nanoparticles and nanoparticle compositions

Номер: US20130101516A1
Автор: YAN Zhao

The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

Подробнее
02-05-2013 дата публикации

C7-Fluoro Substituted Tetracycline Compounds

Номер: US20130109657A1
Принадлежит: Tetraphase Pharmaceuticals Inc

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Подробнее
16-05-2013 дата публикации

INHIBITION OF BACTERIAL BIOFILMS WITH ARYL CARBAMATES

Номер: US20130123225A1
Принадлежит:

Disclosure is provided for carbamate compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same. 8. The compound of claim 1 , wherein n=1 to 5.9. The compound of claim 1 , wherein n=1 to 5 claim 1 , saturated.11. A composition comprising a carrier and an effective amount of the compound of .12. A composition comprising the compound of and a biocide.13. A composition comprising the compound of covalently coupled to a substrate.14. The composition of claim 13 , wherein said substrate comprises a polymeric material.15. The composition of claim 13 , wherein said substrate comprises a solid support.16. The composition of claim 13 , wherein said substrate is selected from the group consisting of a drainpipe claim 13 , glaze ceramic claim 13 , porcelain claim 13 , glass claim 13 , metal claim 13 , wood claim 13 , chrome claim 13 , plastic claim 13 , vinyl claim 13 , and laminate.17. The composition of claim 13 , wherein said substrate is selected from the group consisting of shower curtains or liners claim 13 , upholstery claim 13 , laundry claim 13 , and carpeting.18. A biofilm preventing claim 13 , removing or inhibiting coating composition claim 13 , comprising:(a) a film-forming resin;(b) a solvent that disperses said resin;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(c) an effective amount of the compound of , wherein said effective amount of said compound inhibits the growth of a biofilm thereon; and'}(d) optionally, at least one pigment.19. The coating composition of claim 18 , wherein said compound is covalently coupled to said resin.20. The coating composition of claim 18 , wherein said resin comprises a polymeric material.21. A substrate coated with the coating composition of .22. A method of controlling biofilm formation on a substrate comprising the step of contacting the compound of to said substrate in an amount effective to inhibit ...

Подробнее
16-05-2013 дата публикации

NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF

Номер: US20130123338A1
Принадлежит: Protiva Biotherapeutics, Inc.

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. 2. The cationic lipid of claim 1 , wherein Rand Rare independently selected from the group consisting of a methyl group and an ethyl group.3. The cationic lipid of claim 1 , wherein Rand Rare both methyl groups.4. The cationic lipid of claim 1 , wherein Rand Rare joined to form an optionally substituted heterocyclic ring having from 2 to 5 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen (N) claim 1 , oxygen (O) claim 1 , sulfur (S) claim 1 , and combinations thereof.5. The cationic lipid of claim 1 , wherein X is O claim 1 , C(O)O claim 1 , C(O)N(R) claim 1 , N(R)C(O)O claim 1 , or C(O)S.6. The cationic lipid of claim 1 , wherein Ris selected from the group consisting of hydrogen (H) and an optionally substituted methyl group claim 1 , ethyl group claim 1 , or C-Calkyl claim 1 , alkenyl claim 1 , or alkynyl group.7. The cationic lipid of claim 1 , wherein X is an optionally substituted heterocyclic ring having from 2 to 5 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen (N) claim 1 , oxygen (O) claim 1 , sulfur (S) claim 1 , and combinations thereof.8. The cationic lipid of claim 1 , wherein Y is (CH)and n is 0 claim 1 , 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , or 6.9. The cationic lipid of claim 8 , wherein n is 2 claim 8 , ...

Подробнее
30-05-2013 дата публикации

TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE

Номер: US20130137635A1
Автор: Sands Arthur Thomas
Принадлежит: LEXICON PHARMACEUTICALS, INC.

This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease. 2. The use of claim 1 , wherein the metastatic bone disease is osteosclerotic (osteoblastic).3. The use of claim 2 , wherein the metastatic bone disease is bone metastases of prostate cancer.4. The use of claim 3 , wherein the compound is used in combination with a therapeutically or prophylactically effective amount of a second drug.5. The use of claim 4 , wherein the second drug is a luteinizing hormone-releasing hormone agonist (e.g. claim 4 , leuprolide claim 4 , goserelin claim 4 , buserelin); an antiandrogen (e.g. claim 4 , flutamide claim 4 , nilutamide); or an adrenal gland inhibitor (e.g. claim 4 , ketoconazole claim 4 , aminoglutethimide).6. The use of claim 5 , wherein the second drug is mitoxantrone claim 5 , estramustine claim 5 , doxorubicin claim 5 , etoposide claim 5 , vinblastine claim 5 , paclitaxel claim 5 , carboplatin claim 5 , or vinorelbine.11. The pharmaceutical composition of claim 10 , wherein the second drug is mitoxantrone claim 10 , estramustine claim 10 , doxorubicin claim 10 , etoposide claim 10 , vinblastine claim 10 , paclitaxel claim 10 , carboplatin claim 10 , or vinorelbine. This invention relates to tryptophan hydroxylase inhibitors, compositions comprising them, and methods of their use for the treatment, management and/or prevention of metastatic bone disease.The neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] is involved in multiple central nervous facets of mood control and in regulating sleep, anxiety, alcoholism, drug abuse, food intake, and sexual behavior. In peripheral tissues, serotonin is implicated in the regulation of vascular tone, gut motility, primary hemostasis, and cell-mediated immune responses. Walther, D. J., et al., 299:76 (2003). Some evidence also suggests that serotonin can affect bone growth. See, e.g., ...

Подробнее
13-06-2013 дата публикации

IMINOPROPENE COMPOUND AND USE THEREOF

Номер: US20130150392A1
Принадлежит: Sumitomo Chemical Company, Limited

The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition. 2. The compound according to claim 1 , wherein{'sup': 4', '5, 'sub': '2', 'X is SXor S(O)X'}{'sup': 4', '5', '21', 'A2', '21', 'A2, 'Xand Xare each independently a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or C(=Q)X(wherein, Qis an oxygen atom, and Xis a lower alkyl group optionally substituted), group optionally substituted or a heterocyclic group optionally'}{'sup': 1', '1', 'I1, 'sub': '2', 'Y is OY(wherein, Yis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted or N═C(Y),'}{'sup': B', 'B', 'F', 'F', 'G', 'H', 'G', 'H, 'sub': '2', 'Z is a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower alkenyl group optionally substituted, a higher alkenyl group, a lower cycloalkenyl group optionally substituted, a lower alkynyl group optionally substituted, a higher alkynyl group, an aromatic hydrocarbon group optionally substituted, a heterocyclic group optionally substituted, C(═O)OZ(wherein, Zis a lower alkyl group optionally substituted, a higher alkyl group, a lower cycloalkyl group optionally substituted, a lower ...

Подробнее
20-06-2013 дата публикации

Heteroaryl Nitrile Compounds Useful as Inhibitors of Cathepsin-S

Номер: US20130158018A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same. 4. The compound of the formula (I) according and wherein{'sup': 1', 'c, 'sub': '2', 'Ris t-butyl, sec-butyl, 3-pentyl, cyclohexyl, —CH-cyclohexyl, cyclopentyl, cyclopropyl, phenyl, cyclohexyl-D11, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,1-dioxo-hexahydro-1λ6-thiopyranyl or 1-oxo-hexahydro-1λ4-thiopyranyl, each optionally substituted by an R;'}{'sup': '2', 'Ris hydrogen or methyl;'}{'sup': 1', '2, 'or Rand Rtaken together form a cyclohexyl;'}{'sup': '3', 'sub': '1-7', 'Ris —C(O)Calkyl, —C(O)cyclopropyl, —C(O)cyclopentyl, —C(O)phenyl, —C(O)heterocyclyl wherein the heterocyclyl is chosen from morpholinyl, piperidinyl, tetrahydrofuranyl and tetrahydropyranyl, —C(O)heteroaryl wherein the heteroaryl is chosen from benzofuranyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-a]pyrazinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, thienyl, furanyl, pyrazolyl and pyridinyl,'}{'sub': '2', '—C(O)NH-phenyl, heterocyclyl chosen from 1,1-Dioxo-1λ6-thiomorpholine, tetrahydrofuranyl, 1,1-dioxo-hexahydro-1λ6-thiopyranyl, piperidinyl and 2-oxo-imidazolidinyl, phenyl, cyclohexyl and —CH-thienyl;'}{'sup': 4', '5, 'Rand Rare each independently hydrogen, methyl or n-butyl or'}{'sup': 4', '5, 'Rand Rtaken together may form cyclopropyl, piperidinyl, tetrahydropyranyl or 1-methyl-piperidinyl;'}{'sup': a', 'b, 'R, Rare each independently hydrogen, methyl or phenyl;'}{'sup': 'c', 'Ris methyl, methoxy, cyclohexyl, phenyl, benzyl, fluoro or —C(O)—O-benzyl;'}{'sup': 'd', 'sub': 3', '2', '3', '2', '3', '3', '2', '2', '3', '2', '2', '2', '3, 'Ris independently chosen from methyl, —CF, —CHCF, methoxy, acetyl, —C(O)NH, —C(O)NHCH, —C(O)N(CH), —NH—C(O)-methyl, —S(O)—CH, —S(O)—NH, ...

Подробнее
27-06-2013 дата публикации

THERAPEUTIC AGENT FOR PAIN

Номер: US20130165491A1
Принадлежит: Astellas Pharma Inc.

[Problem] 4. The therapeutic agent for pain according to claim 3 , wherein Ring Ais phenyl which is substituted with —C(O)NHat the 4-position and may be further substituted with halogen.5. The therapeutic agent for pain according to claim 3 , wherein Ring Ais phenyl substituted with halogen.6. The therapeutic agent for pain according to claim 3 , wherein the compound represented by the formula (I-a) or a pharmaceutically acceptable salt thereof of is a compound selected from the group consisting of:3-(2-bromo-4-fluorophenyl)-4-methyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazole,3-(2-chloro-4-fluorophenyl)-4-methyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazole,3-(2-chlorophenyl)-4-methyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazole,3-[1-(4-chloro-2,6-difluorophenoxy)-1-methylethyl]-5-(2-chlorophenyl)-4-methyl-4H-1,2,4-triazole,3-[1-(4-chloro-2,6-difluorophenoxy)-1-methylethyl]-5-(2-chloro-4-fluorophenyl)-4-methyl-4H-1,2,4-triazole,3-(2-fluorophenyl)-4-methyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazole,4-methyl-3-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-5-[3-(trifluoromethyl)-1H-pyrazol-4-yl]-4H-1,2,4-triazole,4-{5-[1-(4-chloro-2,6-difluorophenoxy)-1-methylethyl]-4-ethyl-4H-1,2,4-triazol-3-yl}benzamide,4-{4-isopropyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazol-3-yl}benzamide,4-{5-[1-(4-chloro-2,6-difluorophenoxy)-1-methylethyl]-4-methyl-4H-1,2,4-triazol-3-yl}-3-fluorobenzamide,4-{4-cyclopropyl-5-[1-(2,4-difluorophenoxy)-1-methylethyl]-4H-1,2,4-triazol-3-yl}-3-fluorobenzamide,3-fluoro-4-{4-methyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazol-3-yl}benzamide,4-{5-[1-(4-chloro-2,6-difluorophenoxy)-1-methylethyl]-4-isopropyl-4H-1,2,4-triazol-3-yl}benzamide,3-chloro-4-{4-cyclopropyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazol-3-yl}benzamide, and3-fluoro-4-{4-isopropyl-5-[1-methyl-1-(2,4,6-trifluorophenoxy)ethyl]-4H-1,2,4-triazol-3-yl}benzamide, ora ...

Подробнее
04-07-2013 дата публикации

Process for Preparing Chiral 3-Triazolyl Sulphoxide Derivatives

Номер: US20130172573A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a catalytic process for preparing 3-triazolyl sulphoxide derivatives in enantiomerically pure or enantiomerically enriched form. 2. Process according to claim 1 , characterized in that the enantiomer ratio is 50.5:49.5 to 99.5:0.5 (+):(−) or (−):(+)-enantiomer.3. Process according to either of and claim 1 , characterized in that the enantiomer ratio is 50.5:49.5 to 99.5:0.5 (+):(−) enantiomer.4. Process according to any of to claim 1 , characterized in that{'sup': 1', '2', '1', '2, 'sub': 1', '12, 'Xand X, Yand Yare each independently fluorine, chlorine, hydrogen, (C-C)haloalkyl,'}{'sup': 1', '2, 'sub': 1', '6, 'Rand Rare each independently fluorine, hydrogen, (C-C)alkyl,'}{'sup': '3', 'Ris hydrogen, amino.'}5. Process according to any of to claim 1 , characterized in that{'sup': 1', '2', '1', '2, 'sub': 1', '6, 'Xand X, Yand Yare each independently fluorine, hydrogen, (C-C)haloalkyl,'}{'sup': 1', '2, 'Rand Rare each independently fluorine, methyl,'}{'sup': '3', 'Ris hydrogen.'}6. Process according to any of to claim 1 , characterized in that the oxidizing agents used are organic or inorganic peroxides.8. Process according to any of to claim 1 , characterized in that step (A) is followed by performing a crystallization from organic solvent or a mixture of organic solvent with water.9. Enantiomerically pure or enantiomerically enriched 3-triazolyl sulphoxide derivatives of the formula (I) claim 1 , preparable by the process according to any of to claim 1 , where the enantiomer ratio is 50.5:49.5 to 99.5:0.5 (+):(−)enantiomer. The present invention relates to a catalytic process for preparing 3-thiazolyl sulphoxide derivatives in enantiomerically pure or enantiomerically enriched form.The chemical synthesis of 3-triazolyl sulphoxides is described in the literature, but leads to a racemic mixture (WO 1999/055668).Enantiomerically pure chiral sulphoxides and corresponding derivatives are of great significance in the pharmaceutical and ...

Подробнее
18-07-2013 дата публикации

NOVEL COMPOUNDS

Номер: US20130184248A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

This invention relates to compounds of formula I 2. The compound according to claim 1 , wherein{'sup': '1', 'sub': 2-4', '5-6', '1-5', '3-6', '2', '2', '3', '2', '1-3', '3-6', '1-3, 'Rrepresents phenylethynyl, cyclohexylethynyl, Calkenyl, Ccycloalkenyl, phenyl, furyl, Calkyl or Ccycloalkyl which latter four groups are optionally substituted with one or more substituents selected from fluoro, chloro, cyano, —CH-morpholine, —CH—O—CH, —CHCN, Calkyl, Ccycloalkyl and —O—Calkyl which latter three substituents are optionally substituted with one or more fluorine atoms.'}4. The compound according to claim 3 , whereinA represents N or CH;B represents CH.12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant claim 1 , diluent and/or carrier.13. A method of treating schizophrenia claim 1 , schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses claim 1 , post stroke dementia claim 1 , deficits in concentration claim 1 , mild cognitive impairment claim 1 , the cognitive dysfunction in Alzheimers disease or the cognitive dysfunction of schizophrenia comprising administering to a patient a therapeutically effective amount of a compound according to . This invention relates to substituted triazoles and their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment.Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in ...

Подробнее
18-07-2013 дата публикации

METALLOENZYME INHIBITOR COMPOUNDS

Номер: US20130184309A1
Принадлежит: Viamet Pharmaceuticals, Inc.

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. 137-. (canceled)3942.-. (canceled)43. The method of claim 38 , wherein the disease or disorder is cancer claim 38 , cardiovascular disease claim 38 , inflammatory disease claim 38 , infectious disease claim 38 , metabolic disease claim 38 , ophthalmologic disease claim 38 , central nervous system (CNS) disease claim 38 , urologic disease claim 38 , or gastrointestinal disease.44. The method of claim 38 , wherein the disease or disorder is prostate cancer claim 38 , breast cancer claim 38 , androgen-dependent cancers claim 38 , estrogen-dependent cancers claim 38 , adrenal hyperplasia claim 38 , prostatic hypertrophy claim 38 , virilism claim 38 , hirsutism claim 38 , male pattern alopecia claim 38 , precocious puberty claim 38 , endometriosis claim 38 , uterus myoma claim 38 , uterine cancer claim 38 , mastopathy claim 38 , polycystic ovary syndrome claim 38 , infertility claim 38 , acne claim 38 , functional ovarian hyperandrogenism claim 38 , hyperandrogenism with chronic anovulation claim 38 , hyperandrogenemia claim 38 , premature adrenarche claim 38 , adrenal or androgen excess claim 38 , uterine fibroids claim 38 , inflammatory bowel disease claim 38 , psoriasis claim 38 , systemic fungal infection claim 38 , onychomycosis claim 38 , or cardiovascular disease.4552.-. (canceled)54. The composition of further comprising an additional therapeutic agent.55. The composition of further comprising an additional therapeutic agent that is an anti-cancer agent claim 53 , antifungal agent claim 53 , cardiovascular agent claim 53 , antiinflammatory agent claim 53 , chemotherapeutic agent claim 53 , an anti-angiogenesis agent claim 53 , cytotoxic agent claim 53 , an anti-proliferation agent claim 53 , metabolic disease agent claim 53 , ophthalmologic disease agent claim 53 , central nervous ...

Подробнее
18-07-2013 дата публикации

PROCESS FOR PREPARATION OF RUFINAMIDE

Номер: US20130184469A1
Принадлежит:

The invention relates to a novel, industrially viable, cost effective process for the preparation of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide commonly known as Rufinamide and intermediates thereof. 2. The process according to claim 1 , wherein R is hydrogen claim 1 , methyl or ethyl.3. The process according to claim 1 , wherein formula V is selected from 2-bromoacrylic acid claim 1 , methyl 2-bromoacrylate and ethyl 2-bromo acrylate.4. The process according to claim 1 , wherein the compound of formula VI prepared in step (b) is methyl 1-(2 claim 1 ,6-difluorobenzyI)-1H-1 claim 1 ,2 claim 1 ,3-triazole-4-carboxylate.6. The process according to claim 5 , wherein the compound of formula V is selected from 2-bromoacrylic acid claim 5 , methyl 2-bromoacrylate and ethyl 2-bromo acrylate.7. The process according to claim 5 , wherein the compound prepared is methyl 1-(2 claim 5 ,6-difluorobenzyl)-1H-1 claim 5 ,2 claim 5 ,3-triazole-4-carboxylate.9. The process according to claim 8 , wherein R is hydrogen claim 8 , methyl or ethyl.10. The process according to claim 9 , wherein R is methyl.11. The process according to claim 8 , wherein the brominating agent is selected from the group consisting of phosphorus tribromide claim 8 , aluminum tribromide and bromine.12. The process according to claim 11 , wherein the brominating agent is bromine.13. The process according to claim 8 , wherein the base is selected from the group consisting of sodium carbonate claim 8 , sodium bicarbonate claim 8 , potassium carbonate claim 8 , potassium bicarbonate claim 8 , potassium t-butoxide and triethylamine.14. The process according to claim 13 , wherein sodium carbonate and triethylamine is used as base.15. The process according to claim 8 , wherein the compound prepared is methyl 2-bromoacrylate. The invention provides a novel, industrially viable, cost effective process for manufacturing methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate a key intermediate in the ...

Подробнее
18-07-2013 дата публикации

Process for preparing 5-[1-(4-chlorophenyl)-methylene]-1-hydroxymethyl-2,2-dimethyl-cyclopentanol

Номер: US20130184470A1
Автор: ZIERKE Thomas
Принадлежит:

Process for preparing 5-[1-(4-chlorophenyl)-methylene]-1-hydroxymethyl-2,2-dimethyl-cyclopentanol 18-. (canceled)10. The process according to claim 9 , wherein the reaction a) is carried out at a temperature of (−10) to 40° C.11. The process according to claim 9 , wherein the hydrogenation b) is carried out at a temperature of (−10) to 40° C.12. The process according to claim 9 , wherein the reaction is carried out in a solvent or solvent mixture.13. The process according to claim 12 , wherein catalyst claim 12 , temperature and solvent or solvent mixture is selected such that the diol (Ia) is obtained in an excess relative to the diol (Ib).14. The process according to claim 12 , wherein the hydrogenation is carried out in the presence of a di(C-C-alkyl)formamid claim 12 , di(C-C-alkyl)acetamid or in N-methyl-2-pyrrolidone and palladium is used as catalyst. The present invention relates to a process for preparing diols of the formula (Ia) and (Ib)According to EP-A 359 305, compound (Ia) can be obtained by reacting either the corresponding epoxide (VII) or ester (VIII)wherein Rrepresents a hydrogen atom, an alkyl group or a cycloalkyl group, with a reducing agent, preferably a complex metal hydride, at a temperature from 35° C. to reflux temperature. However, these reagents suffer from being hazardous and expensive. EP-A 359 305 also teaches the use of the diols (Ia) and (Ib) for preparing fungicidal active cyclopentane derivatives such as Metconazole.EP-A 474303 discloses a method of selectively preparing the diol (Ia) from the well obtainable 1-(4-chlorobenzyl)-4,4-dimethyl-cyclohex-1-en-3-on (IX)However, this process requires, besides complex metal hydrides, the use of hydrogen per oxide, which requires challenging safety means in a technical plant.Therefore, it was an object of the present invention to provide a commercial feasible process for preparing the diols of the formula (I) from readily available starting materials, with (Ia) being obtained in an excess ...

Подробнее
01-08-2013 дата публикации

CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES

Номер: US20130197178A1

The present invention provides novel and stable crystalline 1H-1,2,3 triazolium carbenes and metal complexes of 1H-1,2,3 triazolium carbenes. The present invention also provides methods of making 1H-1,2,3 triazolium carbenes and metal complexes of 1H-1,2,3 triazolium carbenes. The present invention also provides methods of using 1H-1,2,3 triazolium carbenes and metal complexes of 1H-1,2,3 triazolium carbenes in catalytic reactions. 84. The compound of any one of - claims 2 , wherein Rand Rare claims 2 , in each instance claims 2 , independently selected from the group consisting of hydrogen claims 2 , methyl claims 2 , ethyl claims 2 , propyl claims 2 , isopropyl claims 2 , butyl claims 2 , isobutyl claims 2 , halogen claims 2 , and hydroxyl.9. The compound of claim 8 , wherein Rand Rare both isopropyl and subscripts m and n are both 2.10. The compound of claim 8 , wherein Ris isopropyl and subscript m is 2.11. The compound of claim 8 , wherein Ris isopropyl and subscript n is 2.12. The compound of claim 8 , wherein Rand Rare both methyl and subscripts m and n are both 3.13. The compound of claim 8 , wherein Ris methyl and subscript m is 3.14. The compound of claim 8 , wherein Ris methyl and subscript n is 3.15. The compound of claim 8 , wherein m and n are both 0.16. The compound of claim 8 , wherein m is 0.17. The compound of claim 8 , wherein n is 0.18. The compound of claim 5 , wherein Rand Rare both isopropyl and subscripts m and p are both 2.19. The compound of claim 5 , wherein Ris isopropyl and subscript m is 2.20. The compound of claim 5 , wherein Ris isopropyl and subscript p is 2.21. The compound of claim 5 , wherein Rand Rare both methyl and subscripts m and p are both 3.22. The compound of claim 5 , wherein Ris methyl and subscript m is 3.23. The compound of claim 5 , wherein Ris methyl and subscript p is 3.24. The compound of claim 5 , wherein m and p are both 0.25. The compound of claim 5 , wherein m is 0.26. The compound of claim 5 , wherein p is 0. ...

Подробнее
08-08-2013 дата публикации

Pesticidal compositions and processes related thereto

Номер: US20130203592A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses molecules having the following formulas (“Formula One” &“Formula Two” and “Formula Three”) The Ar 1 , Het, Ar 2 , R1, R2, R3, R4, and R5 are further described herein.

Подробнее
08-08-2013 дата публикации

PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO

Номер: US20130203593A1
Принадлежит: DOW AGROSCIENCES LLC

This document discloses molecules having the following formulas (“Formula One” & “Formula Two” and “Formula Three”) 2. A molecule according to wherein Aris a substituted phenyl wherein said substituted phenyl has one or more substituents independently selected from C-Chaloalkyl and C-Chaloalkoxy.3. A molecule according to wherein Aris a substituted phenyl wherein said substituted phenyl claim 1 , has one or more substituents independently selected from CF claim 1 , OCF claim 1 , and OCFCF.4. A molecule according to wherein Het is selected from triazolyl claim 1 , imidazolyl claim 1 , or pyrazolyl claim 1 , which can be substituted or unsubstituted.8. A molecule according to wherein Het is a substituted 1 claim 1 ,3-pyrazolyl.10. A molecule according to wherein Aris a phenyl.11. A molecule according to wherein R1 is H or C-Calkyl.12. A molecule according to wherein R1 is H or CH.13. A molecule according to wherein R4 is phenyl claim 1 , C-Calkylphenyl claim 1 , or C-Calkyl-O-phenyl claim 1 , wherein each alkyl and phenyl are optionally substituted with one or more substituents independently selected from F claim 1 , Cl claim 1 , NRR claim 1 , C-Calkyl claim 1 , or C-Calkoxy.14. A molecule according to wherein R5 is unsubstituted.15. A molecule according to wherein Rand Rare independently selected from H and phenyl claim 1 , wherein said phenyl claim 1 , may be optionally substituted with one or more substituents independently selected from F and Cl.16. A molecule according to wherein Het-1 is selected from benzofuranyl claim 1 , benzoisothiazolyl claim 1 , benzoisoxazolyl claim 1 , benzoxazolyl claim 1 , benzothienyl claim 1 , benzothiazolyl cinnolinyl claim 1 , furanyl claim 1 , indazolyl claim 1 , indolyl claim 1 , imidazolyl claim 1 , isoindolyl claim 1 , isoquinolinyl claim 1 , isothiazolyl claim 1 , isoxazolyl claim 1 , oxadiazolyl claim 1 , oxazolinyl claim 1 , oxazolyl claim 1 , phthalazinyl claim 1 , pyrazinyl claim 1 , pyrazolinyl claim 1 , pyrazolyl claim 1 ...

Подробнее
08-08-2013 дата публикации

Pure Intermediate

Номер: US20130203826A1
Принадлежит: Generics Limited

The present invention relates to an improved process for the preparation of Letrozole (I) and its synthetic intermediate 4-[(1-(1,2,4-triazoly)methyl]benzonitrile (III). In particular, it relates to a process to prepare Letrozole and its intermediate (III) substantially free from regioisomeric impurities. The present invention further relates to acid addition salts of 4-[(1-(1,2,4-triazoly)methyl]benzonitrile (III) such as the oxalate salt, and also to Letrozole (I), the intermediate (III) and salts thereof preparable by the processes of the present invention. 153-. (canceled)54. An acid addition salt of 4-[(1-(1 ,2 ,4-triazolyl)methyl]benzonitrile (III) , wherein the acid is not hydrochloric acid.55. An acid addition salt of 4-[(1-(1 ,2 ,4-triazolyl)methyl]benzonitrile (III) , wherein the acid is an organic acid.56. A salt according to claim 54 , wherein the acid:(i) has a pKa (relative to water) of more than −1; and/or(ii) is a carboxylic acid; and/or(iii) is a mono-, a di- or a tri-carboxylic acid; and/or(iv) is a mono-carboxylic acid selected from formic acid, acetic acid, propionic acid or butyric acid; and/or(v) is a di-carboxylic acid selected from oxalic acid, tartaric acid, succinic acid or fumaric acid; and/or(vi) is oxalic acid; and/or(vii) is an organic sulfonic acid; and/or(viii) is an organic sulfonic acid selected from methane sulfonic acid, benzene sulfonic acid or p-toluenesulfonic acid.57. A process for the preparation of a salt according to claim 54 , comprising mixing 4-[(1-(1 claim 54 ,2 claim 54 ,4-triazolyl)methyl]benzonitrile (III) with the acid in a solvent system.58. A process according to claim 57 , wherein:(i) the solvent system comprises one or more solvents selected from straight chain or branched aliphatic ketones and aliphatic C1 to C4 alcohols, or mixtures thereof; and/or(ii) the solvent system comprises one or more solvents selected from straight chain or branched aliphatic ketones and aliphatic C1 to C4 alcohols, or mixtures ...

Подробнее
15-08-2013 дата публикации

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

Номер: US20130210874A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 2. The compound of claim 1 , wherein r is 1.5. The compound of claim 4 , wherein Ris selected from —COOH claim 4 , —SONHR claim 4 , and tetrazol-5-yl.7. (canceled)8. The compound of claim 1 , wherein Ris —Calkyl or —Calkylene-O—Calkylene-R claim 1 , where Ris H.9. The compound of claim 1 , wherein X is —Calkylene- claim 1 , 1 to 4-CH-moieties in the alkylene are each replaced with —NHC(O)— or —C(O)NH—.10. The compound of claim 9 , wherein X is: —C(O)NH—; —CH—NHC(O)—; —(CH)—NHC(O)—; —CH—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—CH—NHC(O)—; —CH—NHC(O)—CH—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—CH—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; or —CH—NHC(O)—(CH)—NHC(O)—CH—CH(COOH)—NHC(O)—.11. The compound of claim 1 , wherein Ris selected from —Calkylene-SR claim 1 , —Calkylene-C(O)NRR claim 1 , —Calkylene-NR—C(O)R claim 1 , —NH—Calkylene-P(O)(OR) claim 1 , —Calkylene-P(O)ORR claim 1 , —Calkylene-CHR—COOH claim 1 , and —Calkylene-C(O)NR—CHR—COOH; Ris H claim 1 , Ris —OH claim 1 , Ris H claim 1 , Ris H claim 1 , Ris H.17. The compound of claim 1 , wherein Ris —Calkyl claim 1 , —Calkylenearyl claim 1 , —Calkyleneheteroaryl claim 1 , or —Calkylene-Ccycloalkyl.18. The compound of claim 1 , wherein Ris H or is taken together with Rto form cyclopentyl.20. (canceled)22. (canceled)23. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.24. The pharmaceutical composition of claim 23 , further comprising a second therapeutic agent selected from the group consisting of diuretics claim 23 , βadrenergic receptor blockers claim 23 , calcium channel blockers claim 23 , angiotensin-converting enzyme inhibitors claim 23 , ATreceptor antagonists claim 23 , neprilysin inhibitors claim 23 , non-steroidal anti-inflammatory agents claim 23 , prostaglandins claim 23 , anti-lipid agents claim 23 , anti-diabetic agents claim 23 , anti-thrombotic ...

Подробнее
22-08-2013 дата публикации

Method for the thermal photoswitching of spin-transition materials, and uses thereof

Номер: US20130214179A1

A method is provided for the thermal photoswitching of spin-transition compounds from the low-spin state to the high-spin state, including at least one step of exposing the material to a non-polarised laser beam which is at room temperature, and the wavelength of which is in the infrared range and the power of which is 1 mW.cm −2 to 1 W.cm −2 . The method may be used for the temporary or permanent marking of materials including particles of at least one spin-transition compound including an iron(II) and triazole ligand compound.

Подробнее
22-08-2013 дата публикации

METHODS AND COMPOSITIONS FOR PROTEIN LABELLING

Номер: US20130216475A1
Принадлежит: Genentech, Inc.

A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce F into proteins with F labelling reagents. This application is a divisional of U.S. Ser. No. 12/712,285 filed on 25 Feb. 2010, and claims the benefit under 35 USC §119(e) of U.S. Provisional Application Ser. No. 61/156,165 filed on 27 Feb. 2009, which is incorporated by reference in entirety.The invention relates generally to methods to conjugate or label groups to proteins. The invention also relates to labelled proteins, and intermediates and reagents useful to prepare labelled proteins for research and clinical development of novel therapeutics and diagnostic tests.Proteins and peptides make up a large part of the armamentarium available for the molecular imaging of cell-surface biomarkers. Targeted proteins produced by genetic engineering are very attractive as PET imaging agents, but labeling with conventional F-based prosthetic groups is problematic due to long synthesis times, poor radiochemical yields, and low specific activity. Although the development of “ideal” imaging agents is an important goal, in practice many imaging agents are developed from existing proteins, such as monoclonal antibodies (Mabs) and their engineered fragments, which are initially developed as potential therapeutic agents or to explore a target's biology. PET imaging agents may function in diagnostic assays or biomarker tests, to enable patient selection, inform decisions around indication choice for therapeutic candidates, and maximize clinical benefit of a therapeutic agent that targets the same receptor or disease pathway. Predictive biomarker tests are conducted before treatment to predict whether a particular treatment is likely to be beneficial. Prognostic biomarkers are correlated with disease outcome and may improve clinical trial design and treatment, and data interpretation confidence levels.The development of Positron Emission Tomographic (PET) ...

Подробнее
22-08-2013 дата публикации

Compounds With Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof

Номер: US20130217887A1
Принадлежит:

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved. 2. The compound of claim 1 , wherein A is a bond.3. The compound of claim 1 , wherein Ris Calkyl.4. The compound of claim 1 , wherein Ris OH.5. The compound of claim 1 , wherein Ris a halo or a radionuclide.6. The compound of claim 1 , wherein Ris Calkyl claim 1 , wherein at least one C of Calkyl is optionally replaced by O claim 1 , S claim 1 , NH claim 1 , C(O).11. The compound of claim 5 , wherein Ris aryl.13. The compound of claim 5 , wherein Ris Calkyl claim 5 , wherein:{'sub': '1-20', 'at least one C of Calkyl is replaced by 0,'}{'sub': '1-20', 'at least one C of Calkyl is replaced by C(O)NH,'}{'sub': '1-20', 'at least one C of Calkyl is replaced by aryl,'}{'sub': '1-20', 'claim-text': 'wherein at least one H of the aryl is replaced by COOH.', 'at least one C of Calkyl is replaced by heteroaryl,'}146. The compound of claim 5 , wherein Ris —[(CH)—O]—.16. The compound of claim 13 , wherein the heteroaryl is a triazole.22. The compound of claim 21 , wherein Xis F.23. The compound of claim 21 , wherein Xis F. This application claims priority to provisional patent application U.S. Ser. No. 61/616,494; filed on Mar. 28, 2012; the entire contents of which are incorporated herein by reference. This application is a continuation-in-part application of, and claims priority to, U.S. Ser. No. 13/155,558; filed on Jun. 8, 2011; the entire contents of which are incorporated herein by reference. This ...

Подробнее
29-08-2013 дата публикации

SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT

Номер: US20130225619A1
Принадлежит: Acucela Inc.

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted heterocyclic amine derivative compound and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. 14. The compound of wherein Y is alkyl claim 1 , carbocyclyl or heterocyclyl.15. The compound of wherein Y is —C(R)(R)(R);{'sup': 16', '17', '16', '17, 'sub': 1', '13, 'Rand Rare each independently selected from hydrogen, C-Calkyl, halo or fluoroalkyl; or Rand R, together with the carbon to which they are attached form a carbocyclyl or heterocyclyl; and'}{'sup': '18', 'Ris selected from a hydrogen, alkyl, alkoxy, hydroxy, halo or fluoroalkyl.'}16. The compound of wherein Rand R claim 15 , together with the carbon to which they are attached claim 15 , form a carbocyclyl or heterocyclyl.17. The compound of wherein Rand R claim 16 , together with the carbon to which they are attached claim 16 , form a cyclobutyl claim 16 , cyclopentyl claim 16 , cyclohexyl claim 16 , cycloheptyl claim 16 , or cyclooctyl claim 16 , and Ris hydrogen or hydroxy.18. The compound of wherein Rand R claim 17 , together with the carbon to which they are attached claim 17 , form a cyclopentyl claim 17 , cyclohexyl claim 17 , or cycloheptyl claim 17 , and Ris hydrogen or hydroxy.19. The compound of wherein Rand Ris independently selected from C-Calkyl; and Ris hydrogen claim 15 , hydroxy or alkoxy.20. The compound of wherein X is selected from —O—C(R) claim 1 , —S(O)—C(R)— claim 1 , —SO(NR)— claim 1 , —NR—C(R)— claim 1 , —NR—C(═O)— claim 1 , and —NR—S(O)—.21. The compound of wherein X is selected from —C(R)—C(R)— claim 1 , —C(R)═C(R)— claim 1 , —C≡C— claim 1 , —C(═O)—N(R)— claim 1 , —C(R)—O— claim 1 , and —C(R)—NR.22. The ...

Подробнее
05-09-2013 дата публикации

Ethynylbenzene derivatives

Номер: US20130231323A1
Автор: Eric J. Toone, Pei Zhou
Принадлежит: Duke University

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R 1 , R 2 , R 3 , R 101 , L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

Подробнее
05-09-2013 дата публикации

NOVEL ORGANOMETALLIC COMPLEXES WHICH EMIT IN THE RED TO GREEN SPECTRAL REGION AND THEIR USE IN OLEDS

Номер: US20130231489A1
Принадлежит: BASF SE

Organometallic complexes which bear at least one ligand which has a unit having a triplet energy of at least 22 000 cm, a process for preparing the organometallic complexes, a mixture comprising at least one inventive organometallic complex, the use of the organometallic complexes or of the mixture in organic light-emitting diodes, the organometallic complexes preferably being used as emitter materials, and specific nitrogen- or phosphorus-substituted triphenylene derivatives and a process for their preparation. 216-. (canceled) The present invention relates to organometallic complexes which bear at least one ligand which has a unit having a triplet energy of at least 22 000 cm, to a process for preparing the organometallic complexes, to a mixture comprising at least one inventive organometallic complex, to the use of the organometallic complexes or of the mixture in organic light-emitting diodes, the organometallic complexes preferably being used as emitter materials, and to specific nitrogen- or phosphorus-substituted triphenylene derivatives and to a process for their preparation.Organic light-emitting diodes (OLEDs) exploit the property of materials to emit light when they are excited by electrical current. OLEDs are of particular interest as an alternative to cathode ray tubes and liquid-crystal displays for the production of flat visual display units and as a particularly efficient light source. Owing to the very compact design and the intrinsically low power consumption, devices comprising OLEDs are suitable especially for mobile applications, for example for applications in cellphones, laptops, digital cameras, etc.The basic principles of the way in which OLEDs function and suitable constructions (layers) of OLEDs are known to those skilled in the art and are specified, for example, in WO 2005/113704 and the literature cited therein. The light-emitting materials (emitters) used may, as well as fluorescent materials (fluorescence emitters), be phosphorescent ...

Подробнее
19-09-2013 дата публикации

TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE

Номер: US20130243727A1
Принадлежит: INFINITY PHARMACEUTICALS, INC.

Provided herein are triazole FASN inhibitors of the formula (I): 2. The method of claim 1 , wherein X is selected from hydrogen claim 1 , —CN claim 1 , —CHO claim 1 , —C(═O)R claim 1 , —C(═O)N(R) claim 1 , —COH claim 1 , —COR claim 1 , —C(═NR)OR claim 1 , —C(═NR)N(R) claim 1 , —C(═S)N(R) claim 1 , —C(═O)SR claim 1 , —C(═S)SR claim 1 , Cperhaloalkyl claim 1 , Caryl claim 1 , and 5-14 membered heteroaryl.3. The method of claim 2 , wherein X is —CN.4. The method of claim 1 , wherein Ris selected from Caryl and 5-14 membered heteroaryl.5. The method of claim 4 , wherein Ris Caryl.7. The method of claim 6 , wherein each of RR claim 6 , R claim 6 , Rand Ris independently selected from hydrogen claim 6 , halogen claim 6 , —CN claim 6 , —OR claim 6 , —N(R) claim 6 , —COH claim 6 , —COR claim 6 , —C(═O)N(R) claim 6 , —SOR claim 6 , Calkyl claim 6 , Calkynyl claim 6 , 3-14 membered heterocyclyl claim 6 , and Caryl; or one or more of Rand R claim 6 , Rand R claim 6 , Rand Ror Rand Rare joined to form a 5-14 membered heteroaryl ring.8. The method of claim 7 , wherein each of R claim 7 , R claim 7 , R claim 7 , Rand Ris independently selected from hydrogen claim 7 , halogen claim 7 , —OR claim 7 , Calkyl claim 7 , and —C(═O)N(R); or Rand Rare joined to form a 5-14 membered heteroaryl ring.10. The method of claim 9 , wherein each of Rand Ris independently halogen.11. The method of claim 10 , wherein each of Rand Ris independently selected from fluoro and chloro.12. The method of claim 1 , wherein Rand Rtogether with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered carbocyclyl claim 1 , heterocyclyl claim 1 , aryl or heteroaryl ring.14. The method of claim 13 , wherein Rand Rare joined to form a Ccarbocyclyl claim 13 , 3-14 membered heterocyclyl claim 13 , Caryl or 5-14 membered heteroaryl ring.15. The method of claim 14 , wherein Rand Rare joined to form a Ccarbocyclyl.16. The method of claim 15 , wherein Q is CRR.17. The method of claim 16 , ...

Подробнее
19-09-2013 дата публикации

COMPOSITIONS AND METHODS FOR QUADRICYCLANE MODIFICATION OF BIOMOLECULES

Номер: US20130244267A1
Принадлежит:

The present disclosure features a strain-promoted [2+2+2] reaction that can be carried out under physiological conditions. In general, the reaction involves reacting a pi-electrophile with a low lying LUMO with a quadricyclane on a biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo and in vitro. The reaction is compatible with modification of living cells. In certain embodiments, the pi-electrophile can comprise a molecule of interest that is desired for delivery to a quadricyclane-containing biomolecule via [2+2+2] reaction. 43. The compound of any of - claims 1 , wherein M is selected from one of the following: nickel (II) claims 1 , palladium (II) claims 1 , platinum (II) claims 1 , cobalt (I) claims 1 , iridium (I) claims 1 , rhodium (I) claims 1 , copper (II) claims 1 , copper (III) claims 1 , silver (III) claims 1 , gold (III) claims 1 , tungsten claims 1 , and iron.53. The compound of any of - claims 1 , wherein nickel (II) claims 1 , palladium (II) claims 1 , and platinum (II).63. The compound of any of - claims 1 , wherein Ar claims 1 , Ar claims 1 , Ar claims 1 , and Arare optional and are aryl claims 1 , substituted aryl claims 1 , heteroaryl claims 1 , or substituted heteroaryl groups.73. The compound of any of - claims 1 , wherein Ar claims 1 , Ar claims 1 , Ar claims 1 , or Aris aryl or substituted aryl.83. The compound of any of - claims 1 , wherein R claims 1 , R claims 1 , R claims 1 , or Ris hydrogen.93. The compound of any of - claims 1 , wherein R claims 1 , R claims 1 , R claims 1 , or Ris alkylene claims 1 , substituted alkylene claims 1 , alkenylene claims 1 , substituted alkenylene claims 1 , alkynylene claims 1 , or substituted alkynylene.103. The compound of any of - claims 1 , wherein Y claims 1 , Y claims 1 , Y claims 1 , or Yis hydrogen or halogen.113. The compound of any of - claims 1 , wherein Y claims 1 , Y ...

Подробнее
19-09-2013 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20130245260A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 13-. (canceled)4. The compound of claim 23 , where Ris selected from —ORand —NRR; Ris H; Ris H or —OH; and Ris H.6. The compound of claim 23 , where Ris —ORand Ris H or —Calkyl.7. The compound of claim 23 , where Ris —OH and Ris —CH.8. (canceled)9. The compound of claim 23 , where Rand Rare taken together to form —CH—CH—.10. The compound of claim 23 , where Z is —CH—.11. The compound of claim 23 , where Z is —N—.1217-. (canceled)18. The compound of claim 23 , where a is 0.19. The compound of claim 23 , where b is 0; or b is 1 and Ris selected from halo claim 23 , —OH claim 23 , and —OCH; or b is 2 and each Ris independently selected from halo and —CH.2022-. (canceled)2429-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/443,828, filed on Feb. 17, 2011; the entire disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to novel compounds having neprilysin-inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat diseases such as hypertension, heart failure, pulmonary hypertension, and renal disease.2. State of the ArtNeprilysin (neutral endopeptidase, EC 3.4.24.11) (NEP), is an endothelial membrane bound Zn metallopeptidase found in many organs and tissues, including the brain, kidneys, lungs, gastrointestinal tract, heart, and the peripheral vasculature. NEP degrades and inactivates a number of endogenous peptides, such as enkephalins, circulating bradykinin, angiotensin peptides, and natriuretic peptides, the latter of which have several effects including, for example, vasodilation and natriuresis/diuresis, as well as inhibition of cardiac hypertrophy and ventricular fibrosis. Thus, NEP plays an important role in blood pressure homeostasis and ...

Подробнее
26-09-2013 дата публикации

Compounds And Methods For Treating Candidiasis And Aspergillus Infections

Номер: US20130252964A1
Принадлежит: POLYMEDIX, INC.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a or species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an infection. 2. The method of wherein each X is S.3. The method of wherein each Ris claim 1 , independently claim 1 , —CH claim 1 , —(CH)—NH claim 1 , —(CH)—NH—C(═NH)NH claim 1 , or —(CH)—NH—C(═O)—R claim 1 , where each n is claim 1 , independently claim 1 , 1 or 2 claim 1 , and each Ris claim 1 , independently claim 1 , H or methyl.49-. (canceled)10. The method of wherein each Ris CF.11. The method of wherein each Vis H and each Vis claim 1 , independently claim 1 , —N—C(═O)—R claim 1 , where each Ris claim 1 , independently claim 1 , —(CH)—NHor —(CH)—NH—C(═NH)NH claim 1 , where each n is claim 1 , independently claim 1 , 1 to 4.1218-. (canceled)19. The method of wherein each Vis H and each Vis —S—R claim 1 , where each Ris —(CH)—NHwhere each n is 2.20. The method of wherein each Ris H claim 1 , —S—(CH)—NH claim 1 , or —S—(CH)—NH—C(═NH)NH claim 1 , where each m is claim 1 , independently claim 1 , 1 to 4.2123-. (canceled)24. The method of wherein:each X is S;{'sup': '1', 'sub': 2', 'n', '2', '2', 'n', '2, 'each Ris, independently, —(CH)—NHor —(CH)—NH—C(═NH)NH, where each n is, independently, 1 to 4;'}{'sup': '2', 'sub': 3', '3', '3, 'each Ris, independently, halo, CF, or C(CH); and'}{'sup': 1', '2', '5', '5, 'sub': 2', 'n', '2, 'each Vis H and each Vis, independently, —S—R, where each Ris, independently, —(CH)—NH, where each n is, independently, 1 to 4.'}2532-. (canceled)3553-. (canceled)5576-. (canceled)7880-. (canceled)82122-. (canceled)124159-. (canceled)161179-. (canceled)181198-. (canceled)200218-. (canceled)220237-. (canceled)239243-. (canceled)245252-. (canceled) The present disclosure was supported by funds from the U.S. Government (NIH/NIDCR Grant No. 2R44DE018371-02) and the U.S. Government may therefore have certain rights in the ...

Подробнее
10-10-2013 дата публикации

Plymorphic Forms of Deferasirox (ICL670A)

Номер: US20130267572A1
Автор: Mutz Michael
Принадлежит: NOVARTIS AG

The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body. 1. A compound which is a crystalline form C of 4-[3 ,5-bis(2-hydroxyphenyl)-[1 ,2 ,4]triazol-1-yl]benzoic acid and which shows on X-ray diffraction a peak at an angle of refraction 2 theta (θ) , of 25.1±0.2° degrees.2. The compound according to claim 1 , having an x-ray diffraction pattern claim 1 , expressed in terms of 2 θ angles claim 1 , that includes five or more peaks selected from the group of peaks at 9.2° claim 1 , 12.4° claim 1 , 13.2° claim 1 , 16.3° claim 1 ,18.3° claim 1 , 21.3° claim 1 , 22.2° claim 1 , 24.2° claim 1 , 25.1°±0.2° degrees.3. The compound according to claim 1 , having substantially the same X-ray diffraction pattern as shown in .4. The crystalline form of 4-[3 claim 1 ,5-bis(2-hydroxyphenyl)-[1 claim 1 ,2 claim 1 ,4]triazol-1-yl]benzoic acid according to any one of claim 1 , which is present in essentially pure form.5. A crystalline form of 4-[3 claim 1 ,5-bis(2-hydroxyphenyl)-[1 claim 1 ,2 claim 1 ,4]triazol-1-yl]benzoic acid which shows an X-ray diffraction diagram of the type shown in claim 1 , in which the relative peak intensities of each peak do not deviate by more than 10% from the relative peak intensities in the diagram shown in .6. A composition comprising 4-[3 claim 1 ,5-bis(2-hydroxyphenyl)-[1 claim 1 ,2 claim 1 ,4]triazol-1-yl]benzoic acid as a solid claim 1 , wherein at least 80% by weight of said solid 4-[3 claim 1 ,5-bis(2-hydroxyphenyl)-[1 claim 1 ,2 claim 1 ,4]triazol-1-yl]benzoic acid its crystalline form C according to .7. The composition according to claim 6 , wherein at least 90% by weight of said solid 4-[3 claim 6 ,5-bis(2-hydroxyphenyl)-[1 claim 6 ,2 claim 6 ,4]triazol-1-yl]benzoic acid is the crystalline form C.8. The ...

Подробнее
17-10-2013 дата публикации

AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS

Номер: US20130274298A1
Принадлежит:

This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. This invention also refers to a pharmaceutical composition comprising at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to methods of treatment or inhibition of tuberculosis and leishmaniasis. 2. The method according to claim 1 , wherein the pharmaceutical composition is employed in the pharmaceutical form of solution claim 1 , suspension claim 1 , emulsion claim 1 , ointment claim 1 , cream claim 1 , gel claim 1 , tablet and/or capsule.3. The method according to claim 2 , wherein the pharmaceutical composition is employed in the pharmaceutical form for oral claim 2 , topical and/or injectable use.4. The method of claim 1 , wherein the azole compound is selected from the group consisting of:1-(3-chlorophenyl)-4-difluoromethyl-1H-1,2,3-triazole,1-(3,5-dichlorophenyl)-4-difluoromethyl-1H-1,2,3-triazole, andone of their salts.5. The method of claim 1 , wherein the azole compound is selected from the group consisting of:(AND)-4-chloride-N-((1-(4-chlorophenyl)-1H-1,2,3-triazole-4-il)methylene)benzenamine,(AND)-4-bromo-N-((1-(4-bromophenyl)-1H-1,2,3-triazole-4-il)methylene)benzenamine, andone of their salts. This is a divisional of co-pending U.S. patent application Ser. No. 12/981,315, filed Dec. 29, 2010, which is a continuation of U.S. application Ser. No. 12/064,241, filed Jun. 16, 2008, now abandoned, which is the U.S. National Stage of International Application No. PCT/BR2006/000169, filed Aug. 21, 2006, which was published in English under PCT Article 21(2), and which claims benefit of priority of Brazilian Patent Application No. PI 0503681-0, filed Aug. 19, 2005, all of which are incorporated herein in their entirety.This invention refers to azole compounds pertaining to the 1,2,3-triazole and imidazole classes that can be used to treat tuberculosis and ...

Подробнее
24-10-2013 дата публикации

COMPOUNDS

Номер: US20130281499A1
Принадлежит:

The present invention relates to substituted triazole compounds of the formula (I): 2. The method according to wherein X represents —CONH— or —CHNH—.3. The method according to wherein Rrepresents phenyl optionally substituted by one claim 1 , two or three groups independently selected from{'sub': 1-6', '3', '1-6', '1-6', '3-6', '3-6, '(a) —Calkyl, —OCH, —Chaloalkyl, —OChaloalkyl, —Ccycloalkyl, —OCcycloalkyl, or halogen;'}(b) phenyl optionally substituted by one, two or three groups independently selected from halogen; and{'sup': '3', 'wherein Rrepresents phenyl optionally substituted by one, two or three groups independently selected from'}{'sub': 1-6', '1-6', '1-6', '2', 'm', '2', 'm', '2', 'n', '2', '2', 'n', '0-6', '2', 'p', '2', 'q', '1-6', '1-6', '1-6', '3-6', '3-6, 'sup': 4', '4', '5', '5', '6', '7', '8', '9, '(a) —Calkyl, —Calkenyl, —Calkoxy, —O(CH)R, —(CH)OC(═O)R, —(CH)COR, —(CH)OC(═O)R, —CalkylOH, —C(═O)NHR, —(CH)NHC(═O)R, —O(CH)NRR, —OCalkylOH, —Chaloalkyl, —OChaloalkyl, —Ccycloalkyl, —OCcycloalkyl or halogen;'}(b) oxazole.4. The method according to wherein Rrepresents —Calkyl.5. The method according to whereinN-[3,4-bis(methyloxy)phenyl]-1-[(4-fluorophenyl)methyl]-5-methyl-1H-1,2,3-triazole-4-carboxamide,N-[3,4-bis(methyloxy)phenyl]-1-[(4-bromophenyl)methyl]-5-methyl-1H-1,2,3-triazole-4-carboxamide,1-[(4-Bromophenyl)methyl]-5-methyl-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Fluorophenyl)methyl]-5-methyl-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Fluorophenyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,1-[(4-Bromophenyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,5-Methyl-1-(phenylmethyl)-N-{4-[(phenylmethyl)oxy]phenyl}-1H-1,2,3-triazole-4-carboxamide,5-Methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1-(phenylmethyl)-1H-1,2,3-triazole-4-carboxamide,1-[(2′-Chloro-4-biphenylyl)methyl]-5-methyl-N-{4-[(3-methylbutyl)oxy]phenyl}-1H-1,2,3- ...

Подробнее
07-11-2013 дата публикации

LIGANDS AND METHODS FOR LABELING BIOMOLECULES IN VIVO

Номер: US20130295019A1

Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system. 2. The ligand of claim 1 , wherein R1 is the same as R2 claim 1 , and/or R4 is the same as R5.1014-. (canceled)15. The method of claim 9 , wherein the subject is a vertebrate.16. (canceled)17. The method of claim 9 , wherein the biomolecule of interest is a lipid claim 9 , protein claim 9 , nucleic acid claim 9 , or a glycan.1820-. (canceled)21. The method of claim 9 , wherein the substrate is a monosaccharide analogue.22. The method of claim 9 , wherein the reporter comprises an azide or alkyne.23. The method of claim 9 , wherein the substrate specific to the biomolecule of interest comprises GDP-fucose claim 9 , CMP-Sia claim 9 , GalNAz claim 9 , or AcManNAz.24. (canceled)25. The method of claim 17 , wherein the substrate specific to the biomolecule of interest comprises an amino acid analogue or a monomeric nucleotide analogue.26. The method of claim 9 , wherein the detectable marker is an azide- or alkyne-conjugated detectable marker.27. The method of claim 9 , wherein the ligand is in complex with Cu(II) as CuSOin a ratio of ligand:CuSOof 2:1 to 6:1.28. (canceled)3045-. (canceled)46. A method of synthesizing 2-(4-((bis((1-tert-butyl-1H-1 claim 9 ,2 claim 9 ,3-triazol-4-yl)methyl)amino)methyl)-1H-1 claim 9 ,2 claim 9 ,3-triazol-1-yl)ethanesulfonic acid (BTTES) comprising:i) reacting 3,3-diethoxy-1-propyne and tert-butyl azide in a mixture of tert-butyl alcohol and water in the presence of sodium bicarbonate, copper(II) sulfate pentahydrate, and sodium ascorbate to produce 1-tert-butyl-4-(diethoxymethyl)-1H-1,2,3-triazole;ii) combining 1-tert-butyl-4-(diethoxymethyl)-1H-1,2,3-triazole with dichloromethane followed by addition of water and trifluoroacetic acid to produce 1-tert-butyl-1H-1,2,3-triazole-4-carbaldehyde;iii) dissolving 1-tert-butyl-1H-1,2,3-triazole-4-carbaldehyde in dichloroethane or THF followed ...

Подробнее
07-11-2013 дата публикации

GLUCAGON RECEPTOR MODULATORS

Номер: US20130296355A1
Принадлежит:

The present invention provides a compound of Formula (I) 2. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein L is —X—CH(R)—; Ris a 5 membered heteroaryl attached through a nitrogen atom to the carbon between Aand Aof the ring containing A claim 1 , A claim 1 , Aand A; Ris hydrogen; and Ris —(CH)COH.3. The compound of or a pharmaceutically acceptable salt thereof claim 2 , wherein X is O.4. The compound of or a pharmaceutically acceptable salt thereof claim 2 , wherein X is NH.5. The compound of or a pharmaceutically acceptable salt thereof wherein Aand Aare each N and Aand Aare each CR; Rat each occurrence is independently H or methyl; B claim 3 , B claim 3 , Band Bare each CR; and Rat each occurrence is H.6. The compound of or a pharmaceutically acceptable salt thereof wherein Ais N and A claim 4 , Aand Aare each CR; Rat each occurrence is independently H or methyl; B claim 4 , B claim 4 , Band Bare each CR; and Rat each occurrence is independently H or methyl.7. The compound of or a pharmaceutically acceptable salt thereof wherein Ris ethyl claim 5 , propyl claim 5 , isopropyl claim 5 , isobutyl claim 5 , neopentyl claim 5 , cyclopropyl claim 5 , cyclobutyl claim 5 , dimethylcyclobutyl claim 5 , cyclopentyl or cyclopropylmethyl.8. The compound of or a pharmaceutically acceptable salt thereof wherein Ris ethyl claim 6 , propyl claim 6 , isopropyl claim 6 , isobutyl claim 6 , neopentyl claim 6 , cyclopropyl claim 6 , cyclobutyl claim 6 , dimethylcyclobutyl claim 6 , cyclopentyl or cyclopropylmethyl.9. The compound of or a pharmaceutically acceptable salt thereof wherein Ris imidazolyl claim 7 , pyrazolyl claim 7 , triazolyl or indazolyl optionally substituted with one to two substituents each independently selected from methyl claim 7 , trifluoromethyl claim 7 , ethyl claim 7 , propyl claim 7 , isopropyl claim 7 , butyl claim 7 , t-butyl claim 7 , methoxy claim 7 , ethoxy claim 7 , cyano claim 7 , chloro or fluoro.10. The compound of ...

Подробнее
14-11-2013 дата публикации

HYBRID MOLECULES CONTAINING PHARMACOPHORES OF FLUCONAZOLE AS ANTIFUNGAL AGENTS AND THEIR PREPARATION

Номер: US20130303579A1
Принадлежит:

Disclosed herein are novel antifungal compounds of Formula 1, containing fluconazole pharmacophore moieties coupled with other moieties including aryl enones and chalcones and pharmaceutically acceptable salts thereof, methods for preparing these compounds and pharmaceutical preparations containing these novel compounds for prevention and treatment of fungal infections. 114-. (canceled)16. The antifungal compound of Formula (1) as claimed in claim 15 , wherein said antifungal compound of Formula (1) is: [{'sup': 1', '1, 'Ais —C═O and Bis —CH═CH—, or'}, {'sup': 1', '1, 'Ais —CH═CH— and Bis —C═O;'}], 'i. Compound 1A, wherein Compound 1A is a compound of Formula (1) wherein either [{'sup': 1', '1, 'Ais —C═O, and Bis a substituted or unsubstituted alkyl or an epoxy ring; or'}, {'sup': 1', '1, 'Ais a substituted or unsubstituted alkyl or an epoxy ring, and Bis —C═O;'}], 'ii. Compound 1B, wherein Compound 1B is a compound of Formula (1), wherein either [{'sup': 1', '1', '5', '6', '7', '8', '9, 'Ais —CH═CH—, and Bis —CH(OR), —C═N—OR, —C═N—Ror —C(X′R)Y′R; or'}, {'sup': 1', '5', '6', '7', '8', '9', '1, 'Ais —CH(OR), —C═N—OR, —C═N—Ror —C(X′R)Y′R, and Bis —CH═CH—;'}], 'iii. Compound 1C, wherein Compound 1C is a compound of Formula (1), wherein either{'sup': 1', '1, 'iv. Compound 1D, wherein Compound 1D is a compound of Formula (1), wherein A-Bis a 3,5-disubstituted (1H)-pyrazole; or'}{'sup': 1', '1, 'v. Compound 1E, wherein Compound 1E is a compound of Formula (1), wherein ABis a 3,5-disubstituted 4,5-dihydro(1H)-pyrazole.'}17. The antifungal compound of Formula (1) as claimed in claim 15 , wherein said antifungal compound of Formula (1) is Compound 1A claim 15 , wherein Compound 1A is a compound of Formula (1) wherein either Ais —C═O and Bis —CH═CH— claim 15 , or Ais —CH═CH— and Bis —C═O.18. The antifungal compound of Formula (1) as claimed in claim 15 , wherein said antifungal compound of Formula (1) is Compound 1B claim 15 , wherein Compound 1B is a compound of Formula (1) ...

Подробнее
21-11-2013 дата публикации

TRIAZOLIDE BASED IONIC LIQUIDS

Номер: US20130310569A1
Принадлежит:

A method of synthesizing an ionic liquid, includes reacting a 1,2,3-triazole including at least one of a 4-substituent or a 5-substituent with a hydroxide compound having the formula ROH in a dehydration reaction, wherein R is an ionic liquid cation. R is a five-membered heterocyclic cation, an aromatic cation, a sulfonium cation, an ammonium cation, or a phosphonium cation. In a number of embodiments, R is a pyridinium cation, a bipyridinium cation, an amino pyridinium cation, a pyridazinium cation, an ozaxolium cation, a pyrazolium cation, an imidazolium cation, a pyramidinium cation, a triazolium cation, a thiazolium cation, an acridinium cation, a quinolinium cation, an isoquinolinium cation, an orange-acridinium cation, a benzotriazolium cation, a methimzolium cation, a sulfonium cation, an ammonium cation, or a phosphonium cation. 1. A method of synthesizing an ionic liquid , comprising: reacting a 1 ,2 ,3-triazole comprising at least one of a 4-substituent or a 5-substituent with a hydroxide compound having the formula ROH in a dehydration reaction , wherein R is an ionic liquid cation.2. The method of wherein R is a five-membered heterocyclic cation claim 1 , an aromatic cation claim 1 , a sulfonium cation claim 1 , an ammonium cation claim 1 , or a phosphonium cation.3. The method of wherein R is a pyridinium cation claim 1 , a bipyridinium cation claim 1 , an amino pyridinium cation claim 1 , a pyridazinium cation claim 1 , an ozaxolium cation claim 1 , a pyrazolium cation claim 1 , an imidazolium cation claim 1 , a pyramidinium cation claim 1 , a triazolium cation claim 1 , a thiazolium cation claim 1 , an acridinium cation claim 1 , a quinolinium cation claim 1 , an isoquinolinium cation claim 1 , an orange-acridinium cation claim 1 , a benzotriazolium cation claim 1 , a methimzolium cation claim 1 , a sulfonium cation claim 1 , an ammonium cation claim 1 , or a phosphonium cation.5. The method of wherein R is an imidazolium cation claim 1 , an ammonium ...

Подробнее
28-11-2013 дата публикации

FUNCTIONALIZED NAPHTHALENE FLUOROPHORES

Номер: US20130315841A1
Принадлежит:

Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted. 1. A functionalized naphthalene fluorophore having a structure:a) 1-(5-(dimethylamino)-2′,2′-dimethyl-1,3-dihydrospiro[cyclopenta[b]naphthalene-2,5′-[1,3]dioxan]-9-yl)ethanone;b) 1-(5-(dimethylamino)-2′,2′-dimethyl-1,3-dihydrospiro[cyclopenta[b]naphthalene-2,5′-[1,3]dioxan]-9-yl)-2,2-dimethylpropan-1-one;c) 1-(2,2-bis(((tert-butyldimethylsilyl)oxy)methyl)-8-(dimethylamino)-2,3-dihydro-1H-cyclo-penta[b]naphthalen-4-yl)ethanone;d) 1-(2′,2′-dimethyl-5-(pyrrolidin-1-yl)-1,3-dihydrospiro[cyclopenta[b]naphthalene-2,5′-[1,3]dioxan]-9-yl)ethanone;e) 1-(8-(dimethylamino)-2,2-bis(hydroxymethyl)-2,3-dihydro-1H-cyclopenta[b]naphthalen-4-yl)ethanone;f) 1-(8-(dimethylamino)-2,2-bis(hydroxymethyl)-2,3-dihydro-1H-cyclopenta[b]naphthalen-4-yl)-2,2-dimethylpropan-1-one;g) 1-(2,2-bis(hydroxymethyl)-8-(pyrrolidin-1-yl)-2,3-dihydro-1H-cyclopenta[b]naphthalen-4-yl)ethanone;h) (8-(dimethylamino)-4-pivaloyl-2,3-dihydro-1H-cyclopenta[b]naphthalene-2,2-diyl)bis(methylene)bis(undec-10-enoate);i) 6-((tert-butyldimethylsilyl)oxy)-1-(8-(dimethylamino)-2,3-dihydro-1H-cyclopenta[b]naphthalen-4-yl)hexan-1-one;j) 1-(8-(dimethylamino)-2,3-dihydro-1H-cyclopenta[b]naphthalen-4-yl)-6-hydroxyhexan-1-one;k) 9-(4-(2-((tert-butyldimethylsilyl)oxy)ethoxy)phenyl)-7-(dimethylamino)-2,3-dihydro-1H-cyclopenta[b]naphthalen-1-one;1) 7-(dimethylamino)-9-(4-(2-hydroxyethoxy)phenyl)-2,3-dihydro-1H-cyclopenta[b]naphthalen-1-one;m) 9-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-7-(dimethylamino)-2,3-dihydro-1H-cyclopenta[b]naphthalen-1-one;n) 7-(dimethylamino)-9-(4-(hydroxymethyl)phenyl)-2,3-dihydro-1H-cyclopenta[b]naphthalen-1-one;o) 2-(4-(6-dimethylamino)-3- ...

Подробнее
28-11-2013 дата публикации

Nuclear Transport Modulators And Uses Thereof

Номер: US20130317031A1
Принадлежит: Karyopharm Therapeutics Inc.

The present invention relates to compounds of formula I: 2. The compound of claim 1 , wherein claim 1 , Ris selected from hydrogen and methyl.3. The compound of claim 2 , wherein Ris hydrogen.4. The compound of claim 1 , wherein Ris O.5. The compound of claim 1 , wherein Ris hydrogen.6. The compound of claim 1 , wherein Ris selected from —N(R)—(C-Ccycloalkyl) claim 1 , —C-Calkyl claim 1 , —(C-Calkylene)-heterocyclyl claim 1 , and —(C-Calkylene)-heteroaryl claim 1 , wherein:{'sup': 3', '5', '5, 'sub': 2', '1', '4, 'any alkyl or alkylene portion of Ris optionally and independently substituted with one or more substituents selected from the group consisting of oxo and —N(R), wherein each Ris independently selected from hydrogen and C-Calkyl;'}{'sup': '3', 'sub': 1', '4, 'any heterocyclyl portion of Rcomprises at least one nitrogen atom in a ring, and is optionally substituted with one or more substituents selected from the group consisting of C-Calkyl and oxo; and'}{'sup': '3', 'sub': 1', '4, 'any heteroaryl portion of Rcomprises at least one nitrogen atom in a ring and is optionally substituted with one or more C-Calkyl.'}7. The compound of claim 6 , wherein Ris —(C-Calkylene)-heterocyclyl.8. The compound of claim 7 , wherein Ris —(Calkylene)-heterocyclyl.9. The compound of wherein the heterocyclyl is selected from pyrazinyl claim 7 , piperidinyl claim 7 , morpholinyl claim 7 , and pyrazolyl.10. The compound of claim 9 , wherein the heterocyclyl is morpholinyl Ris selected from —C(CH) claim 9 , —NH-cyclopropyl claim 9 , —CH-pyrazin-2-yl claim 9 , -pyrazin-2-yl claim 9 , —CH-morpholin-4-yl claim 9 , and 5-methyl-1-H-pyrazol-4-yl.11. The compound of claim 1 , wherein any alkyl claim 1 , alkylene claim 1 , heterocyclyl claim 1 , and heteroaryl portion of Ris optionally and independently substituted with one or more substituents selected from the group consisting of —OH claim 1 , —SH claim 1 , nitro claim 1 , halogen claim 1 , amino claim 1 , cyano claim 1 , C-Calkyl ...

Подробнее
05-12-2013 дата публикации

Photoinduced Alkyne-Azide Click Reactions

Номер: US20130323642A1

The present invention includes a composition comprising an alkyne-based substrate, an azide-based substrate, a Cu(II) salt and a photoinducible reducing agent. The present invention further includes a method of immobilizing a chemical structure in a given pattern onto a section of the surface of a solid substrate, using the photoinducible Cu(I)-catalyzed azide-alkyne cycloaddition Click reaction. 1. A composition comprising an alkyne-based substrate , an azide-based substrate , at least one Cu(II) salt and at least one photoinducible reducing agent , wherein:said alkyne-based substrate comprises at least one reactive alkynyl group, andsaid azide-based substrate comprises at least one reactive azide group.2. The composition of claim 1 , wherein said alkyne-based substrate or said azide-based substrate is attached to a hydrogel.3. The composition of claim 1 , wherein said at least one reactive alkynyl group is a terminal alkynyl group.4. The composition of claim 1 , wherein the molar ratio of said at least one reactive alkyne group and said at least reactive azide group in said composition ranges from about 10to about 10.5. The composition of claim 1 , wherein said at least one photoinducible reducing agent is a Type (I) photoinitiator.8. The method of claim 7 , wherein the molar ratio of said compound of formula (II) and said compound of formula (III) in said first composition ranges from about 0.5 to about 2.9. The method of claim 7 , wherein said at least one reducing agent is a Type (I) photoinitiator.11. The method of claim 7 , wherein said electromagnetic radiation comprises ultraviolet or visible electromagnetic radiation.12. A method of immobilizing a chemical structure in a given pattern onto a section of the surface of a substrate claim 7 , wherein said method comprises the steps of:(i) providing said substrate, wherein at least a portion of said surface of said substrate is derivatized with a given compound, wherein said given compound comprises at least ...

Подробнее
05-12-2013 дата публикации

Indanyloxyphenylcyclopropanecarboxylic acids

Номер: US20130324514A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 , R 3 , m and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

Подробнее
12-12-2013 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20130330365A1
Принадлежит:

In one aspect, the invention relates to compounds having the formula X: 7. The compound of claim 6 , where Ris H and Ris —CHCH.21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of .22. The pharmaceutical composition of claim 21 , further comprising a therapeutic agent selected from adenosine receptor antagonists claim 21 , α-adrenergic receptor antagonists claim 21 , β-adrenergic receptor antagonists claim 21 , β-adrenergic receptor agonists claim 21 , dual-acting β-adrenergic receptor antagonist/α-receptor antagonists claim 21 , advanced glycation end product breakers claim 21 , aldosterone antagonists claim 21 , aldosterone synthase inhibitors claim 21 , aminopeptidase N inhibitors claim 21 , androgens claim 21 , angiotensin-converting enzyme inhibitors and dual-acting angiotensin-converting enzyme/neprilysin inhibitors claim 21 , angiotensin-converting enzyme 2 activators and stimulators claim 21 , angiotensin-II vaccines claim 21 , anticoagulants claim 21 , anti-diabetic agents claim 21 , antidiarrheal agents claim 21 , anti-glaucoma agents claim 21 , anti-lipid agents claim 21 , antinociceptive agents claim 21 , anti-thrombotic agents claim 21 , ATreceptor antagonists and dual-acting ATreceptor antagonist/neprilysin inhibitors and multifunctional angiotensin receptor blockers claim 21 , bradykinin receptor antagonists claim 21 , calcium channel blockers claim 21 , chymase inhibitors claim 21 , digoxin claim 21 , diuretics claim 21 , dopamine agonists claim 21 , endothelin converting enzyme inhibitors claim 21 , endothelin receptor antagonists claim 21 , HMG-CoA reductase inhibitors claim 21 , estrogens claim 21 , estrogen receptor agonists and/or antagonists claim 21 , monoamine reuptake inhibitors claim 21 , muscle relaxants claim 21 , natriuretic peptides and their analogs claim 21 , natriuretic peptide clearance receptor antagonists claim 21 , neprilysin inhibitors claim 21 , nitric oxide donors claim 21 , non ...

Подробнее
12-12-2013 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20130330366A1
Принадлежит:

In one aspect, the invention relates to compounds having the formula XII: 3. The compound of claim 2 , where Ris H and Ris selected from H and —CHCH.5. The compound of claim 4 , where Ris H and Ris selected from H and —CHCH.13. The compound of claim 12 , where Ris H and Ris selected from H claim 12 , —CHOC(O)CH claim 12 , —CHOC(O)OCHCH claim 12 , —CHOC(O)OCH(CH) claim 12 , and —C(O)CH[CH(CH)]—NHC(O)OCH.15. The compound of claim 14 , where R is —CH claim 14 , Ris H claim 14 , and Ris selected from —CHOC(O)CH claim 14 , —CHOC(O)OCH(CH) claim 14 , —CHOC(O)OCHCH claim 14 , and —CHOC(O)CH[CH(CH)]—NHC(O)OCH.19. The compound of claim 18 , where Ris H and Ris selected from —CHOC(O)OCHCHand —CHOC(O)CH[CH(CH)]—NHC(O)OCH.21. The compound of claim 20 , where Ris H claim 20 , Ris —CHOP(O)(OH)or —CHOC(O)CH[CH(CH)]NH claim 20 , and Ris —CHCH; or Ris —C(O)CH[CH(CH)]NH claim 20 , Ris H claim 20 , and Ris —CHCH.23. The compound of claim 22 , where R claim 22 , R claim 22 , and Rare H; or Rand Rare H claim 22 , and Ris —CHOC(O)OCHCH.25. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of .26. The pharmaceutical composition of claim 25 , further comprising a therapeutic agent selected from adenosine receptor antagonists claim 25 , α-adrenergic receptor antagonists claim 25 , β-adrenergic receptor antagonists claim 25 , β-adrenergic receptor agonists claim 25 , dual-acting β-adrenergic receptor antagonist/α-receptor antagonists claim 25 , advanced glycation end product breakers claim 25 , aldosterone antagonists claim 25 , aldosterone synthase inhibitors claim 25 , aminopeptidase N inhibitors claim 25 , androgens claim 25 , angiotensin-converting enzyme inhibitors and dual-acting angiotensin-converting enzyme/neprilysin inhibitors claim 25 , angiotensin-converting enzyme 2 activators and stimulators claim 25 , angiotensin-II vaccines claim 25 , anticoagulants claim 25 , anti-diabetic agents claim 25 , antidiarrheal agents claim 25 , anti- ...

Подробнее
19-12-2013 дата публикации

Compounds for the treatment of proliferative disorders

Номер: US20130338112A1
Принадлежит: Synta Pharmaceuticals Corp.

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

Подробнее
19-12-2013 дата публикации

Compounds for the treatment of neurodegenerative diseases

Номер: US20130338202A1
Принадлежит: Proteo Tech Inc

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Подробнее
26-12-2013 дата публикации

2,4- diaminopyrimidine derivatives

Номер: US20130345180A1
Принадлежит: NOVARTIS AG

There are provided compounds of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as indicated in claim 1 , useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Подробнее
02-01-2014 дата публикации

COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES

Номер: US20140005240A1
Принадлежит:

This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia. 2. The method of claim 1 , wherein the mammal is a human.3. The method of claim 1 , wherein the amount of the compound administered is between 0.1 mg/Kg/day and 1000 mg/Kg/day.4. The method of claim 1 , wherein the amount of compound administered is between 1 mg/Kg/day and 100 mg/Kg/day.5. The method of claim 1 , wherein the amount of compound administered is between 10 mg/Kg/day and 100 mg/Kg/day.6. The method of claim 1 , wherein the tauopathy is selected from the group consisting of Alzheimer's disease claim 1 , Pick's disease claim 1 , progressive supranuclear palsy claim 1 , corticobasal degeneration claim 1 , familial frontotemporal dementia/Parkinsonism linked to chromosome 17 claim 1 , amyotrophic lateral sclerosis/Parkinsonism-dementia complex claim 1 , argyrophilic grain dementia claim 1 , dementia pugilistic claim 1 , diffuse neurofibrillary tangles with calcification claim 1 , progressive subcortical gliosis and tangle only dementia.7. The method of wherein the compound administered is administered by one of routes selected from claim 1 , oral claim 1 , topical claim 1 , systemic or parenteral.8. A method of disrupting or causing the dissolution of tau aggregates in a mammal suffering from a tauopathy claim 1 , comprising administering to the mammal suffering from a tauopathy an effective ...

Подробнее
09-01-2014 дата публикации

CASPASE INHIBITORS AND USES THEREOF

Номер: US20140011847A1
Принадлежит:

This invention provides novel caspase inhibitors useful for prophylaxis or treatment of a number of pathologies, including, for example, Huntington's disease. In certain embodiments the inhibitors include inhibitors of casepase-3 and/or casepase-6. 2. The inhibitor of claim 1 , wherein R4 is selected from the group consisting of H claim 1 , OH claim 1 , and CH3.3. The inhibitor of claim 1 , wherein Ris OH.4. The inhibitor of claim 1 , wherein said inhibitor preferentially inhibits caspase-3 and/or caspase-6 as compared to other caspases.5. The inhibitor of claim 1 , wherein Ar is a substituted aromatic or heteroaromatic.6. The inhibitor of claim 1 , wherein Ar is a halogen substituted aromatic or heteroaromatic.7. The inhibitor of claim 1 , wherein Ar is a fluorine substituted aromatic or heteroaromatic.8. The inhibitor of claim 1 , wherein Ar is 1 claim 1 ,2 claim 1 ,4 claim 1 ,5-tetrafluorophenyl.9. The inhibitor of claim 1 , wherein Ris H or methyl.10. The inhibitor of claim 9 , wherein Ris methyl.11. The inhibitor of claim 1 , wherein Ris cyclohexyl.18. The inhibitor of claim 1 , wherein said inhibitor is in a pharmaceutically acceptable carrier.20. The substrate of claim 19 , wherein R is an R group selected from the R groups listed in Table 3 claim 19 , Table 4 claim 19 , Table 5 claim 19 , Table 6 claim 19 , Table 7 claim 19 , and Table 8.21. The substrate of claim 19 , wherein Ris selected from the group consisting of CHCOOH claim 19 , COOH claim 19 , and OH.22. The substrate of claim 21 , wherein Ris COOH.23. The substrate of claim 19 , wherein Ris selected from the group consisting of CHCOOH claim 19 , COOH claim 19 , and OH.24. The substrate of claim 23 , wherein Ris COOH.25. The substrate of claim 19 , wherein Rand Rare independently selected from the group consisting of H claim 19 , OH claim 19 , and CH.26. The substrate according to claim 25 , wherein Rand Rare H.28. A method of inhibiting a caspase in a mammal claim 1 , said method comprising ...

Подробнее
09-01-2014 дата публикации

Precursor compound connected to solid support for manufacturing 18f radiopharmaceutical, method for manufacturing same, and application thereof

Номер: US20140011961A1

The present invention relates to a solid precursor in the form of an organic salt, the solid precursor having a solid support, a method for manufacturing same, and an application thereof. The solid precursor of the present invention enables omission of the [ 18 F]fluoride refining process using additional cartridge, and the use of excessive phase-transfer catalyst, and can easily remove remaining substance after reaction through the solid support inside the precursor. The solid precursor of the present invention is very appropriate for an automated synthesis device as an all-in-one system that can carry out overall process of [ 18 F]fluorosis reaction, when used by charging in a cartridge.

Подробнее
09-01-2014 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20140011997A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 1. (canceled)2. The process of claim 18 , where X is selected from pyrazole claim 18 , imidazole claim 18 , triazole claim 18 , benzotriazole claim 18 , furan claim 18 , pyrrole claim 18 , tetrazole claim 18 , pyrazine claim 18 , thiophene claim 18 , oxazole claim 18 , isoxazole claim 18 , thiazole claim 18 , isothiazole claim 18 , oxadiazole claim 18 , thiadiazole claim 18 , pyridazine claim 18 , pyridine claim 18 , pyrimidine claim 18 , pyran claim 18 , benzimidazole claim 18 , benzoxazole claim 18 , benzothiazole claim 18 , pyridylimidazole claim 18 , and pyridyltriazole.3. The process of claim 2 , where X is selected from pyrazole claim 2 , triazole claim 2 , benzotriazole claim 2 , tetrazole claim 2 , oxazole claim 2 , isoxazole claim 2 , thiazole claim 2 , pyridazine claim 2 , pyrimidine claim 2 , and pyridyltriazole.4. The process of claim 18 , where Ris selected from —ORand —NRR claim 18 , where Ris H claim 18 , Ris H or —OH claim 18 , and Ris H.7. The process of claim 18 , where Ris H.8. The process of claim 18 , where Ris absent or is selected from H; halo; —Calkylene-OH; —NH; —Calkyl; —CF; —Ccycloalkyl; —Calkylene-O—Calkyl; —C(O)R; —Calkylene-COOR; —C(O)NRR; —NHC(O)R; ═O; —NO; —C(CH)═N(OH); phenyl optionally substituted with one or two groups independently selected from halo claim 18 , —OH claim 18 , —CF claim 18 , —OCH claim 18 , —NHC(O)CH claim 18 , and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl optionally substituted with methyl; thiophenyl optionally substituted with methyl or halo; furanyl; and —CH-morpholinyl; and Ris H.10. The process of claim 18 , where Ris absent or is selected from H; halo; —Calkylene-OH; —Calkyl; —Ccycloalkyl; —Calkylene-O—Calkyl; —C(O)R; —Calkylene-COOR; —C(O)NRR; —NHC(O)R; —NHC(O)R; ═O; phenyl optionally substituted with one or two groups independently selected from halo claim 18 , —OH claim 18 , and —OCH; pyridinyl; and pyrazinyl; Ris —Calkyl; ...

Подробнее
16-01-2014 дата публикации

N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS

Номер: US20140018318A1
Принадлежит: The Scipps Research Institute

The present invention provides inhibitors of a wide variety of serine hydrolase enzymes. The inhibitors of the present invention are N1- and N2-carbamoyl-1,2,3-triazole compounds such as those of Formula (I): 3. The triazole compound of claim 2 , wherein Xis CH.4. The triazole compound of claim 2 , wherein Ris benzyl.5. The triazole compound of claim 1 , wherein Ror Ris diphenylmethanolyl.6. The triazole compound of claim 1 , wherein Ror Ris 4-phenyloxyphenyl.7. The triazole compound of claim 1 , wherein Ror Ris phenyl or naphthyl optionally substituted by a moiety selected from the group consisting of halo claim 1 , hydroxyl claim 1 , carboxyl claim 1 , NO claim 1 , Calkyl (optionally substituted by one claim 1 , two claim 1 , or three substituents each independently selected from hydroxyl claim 1 , cyano claim 1 , or halo) claim 1 , and Calkoxy (optionally substituted by one claim 1 , two claim 1 , or three substituents each independently selected from hydroxyl claim 1 , cyano claim 1 , and halo).9. The triazole compound of claim 1 , wherein Ris H.10. The triazole compound of claim 1 , wherein Ris H.15. The triazole compound of wherein w is 1 claim 14 , and Ris H.16. The triazole compound of wherein Ris phenyl or biphenyl claim 14 , optionally substituted with one claim 14 , two claim 14 , or three substituents each independently selected from the group consisting of: Calkyl claim 14 , Chydroxyalky claim 14 , Calkoxy claim 14 , Cperfluoroalkoxy claim 14 , halogen claim 14 , and hydroxyl.19. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.20. A method of inhibiting a serine hydrolase enzyme comprising contacting the serine hydrolase enzyme with a compound of .21. A method of inhibiting diacylglycerol lipase β (DAGLB) comprising contacting DAGLB with a compound of .24. (canceled)25. A method of treating pain claim 1 , comprising administering to a patient in need thereof an effective amount of a compound of .26. A ...

Подробнее
23-01-2014 дата публикации

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

Номер: US20140024835A1
Принадлежит: THERAVANCE, INC.

The invention is directed to compounds having the formula: 14-. (canceled)5. The process of claim 33 , wherein Ris selected from —COOH claim 33 , —SONHR claim 33 , and tetrazol-5-yl.6. (canceled)7. The process of claim 33 , wherein Y represents —C(R)— claim 33 , Z is —N— claim 33 , Q is —N— and W is a bond.8. The process of claim 33 , wherein Y represents —C(R)— claim 33 , Z is —CH— claim 33 , Q is —C(R)— and W is —C(O)—.9. The process of claim 33 , wherein Y represents —N— claim 33 , Z is —C(R)— claim 33 , Q is —C(R)— and W is a bond.10. The process of claim 33 , wherein Y represents —C(R)— claim 33 , Z is —CH— claim 33 , Q is —N— and W is a bond.11. The process of claim 33 , wherein Ris selected from H claim 33 , halo claim 33 , —Calkyl claim 33 , —Ccycloalkyl claim 33 , and —Calkylene-OR.12. The process of claim 33 , wherein Ris selected from —Calkyl and —Calkylene-O—Calkylene-R claim 33 , where Ris —Calkyl.1314-. (canceled)15. The process of claim 33 , wherein X is selected from: —C(O)NH—; —CH—NHC(O)—; —C(O)NH—CH—; —C(O)NH—NHC(O)—; —CH═C(—CH-2-thiophene)-C(O)NH—; —(CH)—NHC(O)—; —C(O)NH—CH—CH(COOH)—CH—; —C(O)NH—CH(benzyl)-CH—NHC(O)—; —C(O)NH—CH(benzyl)-CH—C(O)NH—; —CH—NHC(O)—CH—NHC(O)—; —CH—NHC(O)-cyclohexylene-NHC(O)—; —CH—N(OH)C(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—CH—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—C(O)N(OH)—CH—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; and —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—.16. The process of claim 15 , wherein X is selected from ...

Подробнее
23-01-2014 дата публикации

CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE

Номер: US20140024837A1
Принадлежит: UNIVERSITE DE MONTREAL

A compound of Formula I or Formula II: 3. The compound of claim 2 , wherein X is H.4. The compound of claim 2 , wherein X is NO. This application is a continuation of U.S. Ser. No. 12/602,425 (now allowed), which was filed on Apr. 15, 2010 as the United States national stage entry of PCT/CA2008/001049, which was filed on May 29, 2008 and claims priority to U.S. Provisional App. No. 60/940,523, filed on May 29, 2007. The entire contents of each of the above-cited applications are incorporated herein in their entireties.The present invention concerns cinnamoyl inhibitors of transglutaminase.Transglutaminases (TGases, EC 2.3.2.13) are calcium-dependent enzymes that catalyze the intermolecular cross-linking of certain proteins through the formation of γ-glutamyl-ε-lysine side chain bridges. In mammals, three types of TGases have been characterized to date and are found in tissue, plasma and epidermis. Tissue TGases are involved in diverse biological processes such as endocytosis, apoptosis and cell growth regulation. The plasma-soluble form of TGase, Factor XIIIa, stabilizes blood clots by catalyzing the cross-linking of fibrin during hemostasis. Epidermal TGase plays a key role in the synthesis of the cornified envelope of epidermal keratinocytes.Unregulated, high TGase activities have been linked to physiological disorders involved in disease states such as acne, cataracts, immune system diseases, psoriasis, neuropathy, neurodegenerative disease such as, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, Celiac disease, cancer metastasis, inflammation, fibrosis, diabetes, autoimmune diseases, lamellar ichthyosis, psoriasis, supranuclear palsy, renal failure. Potent and selective TGase inhibitors offer means for elucidating the roles of TGases in various disease states and may serve as lead compounds for therapeutic development.In recent years, TGase activity has been shown to be regulated by a number of potential TGase inactivators, including ...

Подробнее
30-01-2014 дата публикации

Iminopropene compound and use thereof

Номер: US20140031376A1
Принадлежит: Sumitomo Chemical Co Ltd

The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.

Подробнее
30-01-2014 дата публикации

Process for the Syntheses of Triazoles

Номер: US20140031402A1
Принадлежит: Rib X Pharmaceuticals Inc

The present invention relates to processes for the preparation of triazoles. These compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

Подробнее
06-02-2014 дата публикации

Imidazole, Pyrazole, and Triazole Derivatives Useful As Antibacterial Agents

Номер: US20140038975A1
Принадлежит:

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections. 2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof; [{'sup': '1', 'sub': 1', '3, 'Ris (C-C)alkyl;'}, {'sup': '2', 'sub': 1', '3, 'Ris (C-C)alkyl;'}, {'sup': '3', 'sub': 1', '3, 'Ris hydrogen or (C-C)alkyl;'}, 'X is N;', {'sup': '4', 'Y is N or CR;'}, {'sup': '4', 'sub': 1', '3, 'Ris hydrogen or (C-C)alkyl;'}, {'sub': 2', '6', '2', 'n', '2', 'p', '2', 'n', '2', 'p, 'L is a bond, (C-C)alkynylene, —(CH)O—(CH)—, or —(CH)S(CH)—;'}, 'n is 0, 1, or 2;', 'p is 0, 1, or 2;', {'sup': '7', 'sub': 1', '6', '6', '12', '5', '8', '3', '8', '5', '12', '3', '13, 'Ris (C-C)alkyl, (C-C)aryl, cyano, (C-C)cycloalkenyl, (C-C)cycloalkyl, (C-C)heteroaryl, or (C-C)heterocycle; and'}, {'sup': '8', 'sub': 6', '12', '6', '12', '1', '6', '3', '8', '5', '12, 'Ris absent, (C-C)aryl, (C-C)aryl(C-C)alkyl, (C-C)cycloalkyl, or (C-C)heteroaryl.'}], 'wherein3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof; [{'sup': '1', 'Ris methyl;'}, {'sup': '2', 'Ris methyl;'}, {'sup': '3', 'Ris hydrogen or methyl;'}, 'X is N;', {'sup': '4', 'Y is N or CR;'}, {'sup': '4', 'Ris hydrogen or methyl;'}, {'sub': 2', '6', '2', 'n', '2', 'p', '2', 'n', '2', 'p, 'L is a bond, (C-C)alkynylene, —(CH)O—(CH)—, or —(CH)S(CH)—;'}, 'n is 0, 1, or 2;', 'p is 0, 1, or 2;', {'sup': '7', 'sub': 6', '12', '6', '12', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6, 'Ris (C-C)aryl, wherein the (C-C)aryl is dihydroindenyl, naphthyl, phenyl, or tetrahydronaphthalenyl, wherein each is optionally substituted with 1, 2, or 3 substituents that are independently (C-C)alkoxy, (C-C)alkyl, (C-C)alkylthio, cyano, ethylenedioxy, halo(C-C)alkoxy, halo(C-C)alkyl, halogen, hydroxy, or oxo; and'}, {'sup': '8', 'sub': 3', '8', '5', '12, 'Ris absent, (C-C)cycloalkyl, or (C-C)heteroaryl.'}], 'wherein4. The compound ...

Подробнее
06-02-2014 дата публикации

PROCESS FOR THE PREPARATION OF DEFERASIROX

Номер: US20140039199A1
Принадлежит:

The present invention provides improved process for the preparation of Deferasirox of formula (I). 17.-. (canceled)8. A method for preparing Deferasirox comprising the step of:treating 2-(2-hydroxyphenyl)benz [1,3]oxazin-4-one with 4-hydrazinobenzoic acid in the presence of a dehydrating agent, a suitable solvent, and optionally in the presence of water.9. The method of claim 8 , wherein the dehydrating reagent is potassium hydrogen sulfate claim 8 , sodium hydrogen sulfate claim 8 , or a mixture thereof.10. The method of claim 8 , wherein the suitable solvent is a C-Calcohol.11. A method for purifying Deferasirox comprising:suspending Deferasirox in a polar organic solvent to provide a suspension;{'sub': 2', '2, 'adding 30% HOand water to the suspension to provide a reaction mass;'}optionally heating the reaction mass at 25-35° C.;filtering the reaction mass to provide a filtered solid mass and washing the filtered solid mass with water to provide a wet cake;charging the wet cake in water and stirring at 55-85° C. to provide a suspended solid product; andfiltering the suspended solid product to provide a filtered solid product and washing the filtered solid product with water to provide purified Deferasirox substantially free of hydrazine impurity.12. The method of claim 11 , wherein the polar organic solvent comprises dimethylsulfoxide claim 11 , dimethylformamide claim 11 , hexamethylphosphorotriamide claim 11 , or tetrahydrofuran.13. The method of claim 12 , wherein the polar organic solvent comprises dimethylformamide.14. A method for purifying Deferasirox comprising:suspending crude Deferasirox in a methanol:ethyl acetate solvent to provide a mixture;heating the mixture;optionally treating the mixture with carbon or silica gel;adding water to the mixture and heating the mixture;partially removing the solvent, to yield a mixture comprising crystals;filtering the crystals; anddrying the filtered crystals to provide purified Deferasirox. The present invention ...

Подробнее
13-02-2014 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20140045906A1
Принадлежит:

In one aspect, the invention relates to compounds having the formula: 6. The compound of claim 5 , where Ris selected from —CH claim 5 , —OCH claim 5 , and Cand Ris H; or Ris selected from H claim 5 , —CH claim 5 , Cl claim 5 , and F claim 5 , and Ris Cl; or Ris H and Ris selected from —CHand —CN; Ris selected from H claim 5 , —Calkyl claim 5 , and —(CH)ORwhere Ris H or —CH; and Ris H.10. The compound of claim 9 , where Ris F claim 9 , Ris Cl claim 9 , Ris H claim 9 , Ris —OCHor —OCHCH claim 9 , and Ris H.14. The compound of claim 13 , where Ris F claim 13 , Ris Cl claim 13 , Ris H claim 13 , and Ris H.17. The compound of claim 16 , where Rand Rare H; Ris selected from —Calkyl claim 16 , —(CH)OR claim 16 , and —(CH)NRR; Ris selected from —OH claim 16 , —OCH claim 16 , —OCHCH claim 16 , and —Calkyl; and Ris H.18. The compound of claim 17 , where Rand Rare H claim 17 , Ris —CH claim 17 , Ris —OH or —OCH claim 17 , and Ris H.20. The compound of claim 19 , where Ris H claim 19 , Ris Cl claim 19 , Ris H claim 19 , —CH claim 19 , —CHCHor —(CH)OH claim 19 , Ris —OH or —OCH claim 19 , and Ris H; or Ris F claim 19 , Ris Cl claim 19 , Ris H or —Calkyl claim 19 , Ris —OH claim 19 , —OCHor —Calkyl claim 19 , and Ris H.22. The compound of claim 21 , where Ris H or F; Ris Cl; Ris H or —Callyl; Ris —OCH claim 21 , —OCHCH claim 21 , or —Calkyl; R claim 21 , if present claim 21 , is H; and Ris H.24. The compound of claim 23 , where Ris F claim 23 , Ris Cl claim 23 , Ris H or —Calkyl claim 23 , R claim 23 , if present claim 23 , is H claim 23 , and Ris H.27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of .28. The pharmaceutical composition of claim 27 , further comprising a therapeutic agent selected from adenosine receptor antagonists claim 27 , α-adrenergic receptor antagonists claim 27 , β-adrenergic receptor antagonists claim 27 , β-adrenergic receptor agonists claim 27 , dual-acting β-adrenergic receptor antagonist/α-receptor ...

Подробнее
13-02-2014 дата публикации

NEPRILYSIN INHIBITORS

Номер: US20140046053A1
Принадлежит: THERAVANCE, INC.

In one aspect, the invention relates to compounds having the formula: 14-. (canceled)5. The compound of claim 22 , where Ris selected from —ORand —NRR claim 22 , Ris H claim 22 , Ris H or —OH claim 22 , and Ris H.8. The compound of claim 22 , where Ris —NRR claim 22 , where Ris H and Ris H.9. The compound of claim 22 , where Ris H.1015-. (canceled)16. The compound of claim 22 , where a is 0; or a is 1 and Ris 3-chloro.17. The compound of claim 22 , where b is 0; or b is 1 and Ris 3′-chloro claim 22 , 3′-methyl claim 22 , or 2′-methoxy; or b is 2 and Ris 2′-fluoro-5′-chloro claim 22 , 2′ claim 22 ,5′-dichloro claim 22 , 2′-methyl-5′-chloro claim 22 , or 3′-chloro-5′-hydroxy.18. The compound of claim 22 , where the methylene linker on the biphenyl is substituted with 2 methyl groups.20. The compound of claim 22 , where{'sup': 1', '7, 'Ris —OR;'}{'sup': '2', 'Ris H;'}{'sup': '5', 'a is 0; or a is 1 and Ris 3-chloro;'}{'sup': 6', '6, 'b is 0; or b is 1 and Ris 3′-chloro, 3′-methyl, or 2′-methoxy; or b is 2 and Ris 2′-fluoro-5′-chloro, 2′,5′-dichloro, 2′-methyl-5′-chloro, or 3′-chloro-5′-hydroxy;'}andthe methylene linker on the biphenyl is optionally substituted with 2 methyl groups.21. (canceled)2328-. (canceled) This application claims the benefit of U.S. Provisional Application No. 61/423,180, filed on Dec. 15, 2010; the entire disclosure of which is incorporated herein by reference.1. Field of the InventionThe present invention relates to novel compounds having neprilysin-inhibition activity. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat diseases such as hypertension, heart failure, pulmonary hypertension, and renal disease.2. State of the ArtNeprilysin (neutral endopeptidase, EC 3.4.24.11) (NEP), is an endothelial membrane bound Zn+ metallopeptidase found in many organs and tissues, including the brain, kidneys, lungs, ...

Подробнее
20-02-2014 дата публикации

Blood brain barrier-penetrating oximes for cholistenerases reactivation

Номер: US20140051712A1
Принадлежит: Individual

The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.

Подробнее
27-02-2014 дата публикации

Triazole compounds as ksp inhibitors

Номер: US20140056880A1
Принадлежит: NOVARTIS AG

The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.

Подробнее
06-03-2014 дата публикации

Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto

Номер: US20140066369A1
Принадлежит: ARENA PHARMACEUTICALS, INC.

The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto. 3. The compound according to claim 1 , wherein Ar is selected from: aryl and heteroaryl; each optionally substituted with one or more substituents selected from: chloro claim 1 , cyano claim 1 , dimethylcarbamoyl claim 1 , cyclopropylsulfonyl claim 1 , fluoro claim 1 , imidazolyl claim 1 , methyl claim 1 , methylpyrazolyl claim 1 , methylsulfonyl claim 1 , pyrrolyl claim 1 , tetrazolyl claim 1 , triazolyl claim 1 , and trifluoromethylthio.4. The compound according to claim 1 , wherein Ar is selected from: 2-chloro-4-(methylsulfonyl)phenyl claim 1 , 2-fluoro-4-(1H-1 claim 1 ,2 claim 1 ,3-triazol-1-yl)phenyl claim 1 , 2-fluoro-4-(1H-1 claim 1 ,2 claim 1 ,4-triazol-1-yl)phenyl claim 1 , 2-fluoro-4-(1H-imidazol-1-yl)phenyl claim 1 , 2-fluoro-4-(1H-pyrrol-1-yl)phenyl claim 1 , 2-fluoro-4-(1H-tetrazol-1-yl)phenyl claim 1 , 2-fluoro-4-(2H-1 claim 1 ,2 claim 1 ,3-triazol-2-yl)phenyl claim 1 , 2-fluoro-4-(4H-1 claim 1 ,2 claim 1 ,4-triazol-4-yl)phenyl claim 1 , 2-fluoro-4-(4-methyl-1H-pyrazol-1-yl)phenyl claim 1 , 2-fluoro-4-(methylsulfonyl)phenyl claim 1 , 2-methyl-6-(methylsulfonyl)pyridin-3-yl claim 1 , 3-chloro-4-(methylsulfonyl)phenyl claim 1 , 4-(1H-1 claim 1 ,2 claim 1 ,4-triazol-1-yl)phenyl claim 1 , 4-(1H-tetrazol- ...

Подробнее
06-03-2014 дата публикации

METHOD OF SEPARATING CARBON NANOTUBES

Номер: US20140066631A1
Принадлежит:

Provided is a method of separating carbon nanotubes, the method comprising: forming first carbon nanotubes having a first functional group, forming a substrate having a second functional group, and causing the first carbon nanotubes to adhere to the substrate by a click chemistry reaction between the first functional group and the second functional group. 1. A method of separating carbon nanotubes , the method comprising:forming first carbon nanotubes having a first functional group;forming a substrate having a second functional group;adhering the first carbon nanotubes to the substrate by a click chemistry reaction between the first functional group and the second functional group.2. The method of claim 1 , wherein the first functional group is an alkyne functional group claim 1 , and the second functional group is an azide functional group.3. The method of claim 2 , further comprising forming a first compound on the substrate by the click chemistry reaction.4. The method of claim 3 , wherein the first carbon nanotubes are connected to the substrate by the first compound.5. The method of claim 3 , wherein the first compound is triazole.6. The method of claim 1 , wherein the second functional group is the azide functional group claim 1 , and the forming of the substrate having the second functional group comprises forming an active layer on a bare substrate and bonding the second functional group onto the active layer.7. The method of claim 6 , further comprising forming an adhesive layer on the bare substrate before the forming of the active layer.8. The method of claim 6 , wherein the bonding of the second functional group onto the active layer comprises forming a first mixed solution of the azide functional group and a polymer compound and immersing the bare substrate in the first mixed solution.9. The method of claim 8 , wherein the polymer compound is polyacrylic acid claim 8 , and the active layer contains the polyacrylic acid.10. The method of claim 1 , ...

Подробнее
06-03-2014 дата публикации

COPPER-CATALYSED LIGATION OF AZIDES AND ACETYLENES

Номер: US20140066632A1
Принадлежит: The Scripps Research Institute

A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal. 1. A copper catalyzed process for preparing a 1 ,4-disubstituted 1 ,2 ,3-triazole comprising:contacting a human blood plasma solution of an organic azide and a terminal alkyne with a source of catalytic Cu(I) ion to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole.2. The process of wherein the solution further comprises at least one ligand comprising at least one functional group selected from the group consisting of a nitrile claim 1 , an isonitrile claim 1 , a primary amine claim 1 , a secondary amine claim 1 , a tertiary amine claim 1 , a nitrogen bearing heterocycle claim 1 , a carboxylate claim 1 , a halide claim 1 , an alcohol claim 1 , a thiol claim 1 , a sulfide claim 1 , a phosphine claim 1 , and a phosphite.3. The process of wherein the solution further comprises at least one ligand comprising a nitrogen bearing heterocycle group.4. The process of wherein the solution further comprises at least one polyvalent ligand comprising one or more functional groups selected from the group consisting of a nitrile claim 1 , an isonitrile claim 1 , a primary amine claim 1 , a secondary amine claim 1 , a tertiary amine claim 1 , a nitrogen bearing heterocycle claim 1 , a carboxylate claim 1 , a halide claim 1 , an alcohol claim 1 , a thiol claim 1 , a sulfide claim 1 , a phosphine claim 1 , and a phosphite.5. The process of wherein the solution further comprises at least one polyvalent ligand comprising one or more nitrogen bearing heterocycle groups.6. The process of wherein the solution ...

Подробнее
20-03-2014 дата публикации

Small molecule inhibitors of trpa1

Номер: US20140080842A1

The present invention relates to the use of compounds which are capable of attenuating skin irritation when they are applied to the skin. Skin irritation can be caused, inter alia, by ingredients of cosmetic or pharmaceutical compositions and/or environmental irritants. In particular, the present invention relates to compounds having the property of antagonizing the activation of the transient receptor potential (TRP) ankyrin 1 (TRPA1) ion channel and the use of said compounds as soothing agents. Such compounds can be used in many fields, particularly in personal-care products, cosmetics, textile and packaging products, pharmaceutical compositions, medical devices, and foodstuffs. The present invention further relates to products and/or pharmaceutical compositions containing said compounds. The present invention also relates to the use of the compounds described herein for the modulation of the taste of a food product.

Подробнее
27-03-2014 дата публикации

DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES

Номер: US20140088048A1
Принадлежит: Merck Sharp & Dohme Corp.

A compound having the structure 3. A compound of claim 1 , wherein Ris hydrogen or —CH claim 1 , or a pharmaceutically acceptable salt thereof.4. A compound of claim 1 , wherein Ris hydrogen or —CH claim 1 , or a pharmaceutically acceptable salt thereof.5. A compound of claim 1 , wherein Ris hydrogen or —CH claim 1 , or a pharmaceutically acceptable salt thereof.6. A compound of claim 1 , wherein Ris hydrogen or —CH claim 1 , or a pharmaceutically acceptable salt thereof.10. A compound of claim 1 , wherein claim 1 , Ris hydrogen claim 1 , —CH claim 1 , or —CHCH claim 1 , or a pharmaceutically acceptable salt thereof.11. A compound of claim 1 , wherein claim 1 , Ris —C(CH) claim 1 , or a pharmaceutically acceptable salt thereof.13. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.14. A pharmaceutical composition comprising a compound of claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , and a pharmaceutically acceptable carrier.15. A pharmaceutical composition comprising a compound of claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , a diuretic claim 12 , and a pharmaceutically acceptable carrier.16. A method for treating hypertension in a patient which comprises administering to the patient a therapeutically effective amount of the composition of . WO09103875 describes diazeniumdiolate dihydro indole derivatives of a specified formula for treating hypertension and cardiovascular disease. WO07144512 describes diazeniumdiolate tetrazole-biphenyl derivatives of a specified formula for treating hypertension and cardiovascular disease. US 2005137191 describes nitrate ester compounds, e.g., 1,2-dichloro-4-(2-methyl-butyldisulfanyl)-benzene, useful for preventing or mitigating tissue and/or cellular damage associated with aging, septic shock, ulcers, gastritis, ulcerative colitis and Crohn's disease. US 2005065194 describes use ...

Подробнее
03-04-2014 дата публикации

Triazole compound and use thereof

Номер: US20140094362A1
Принадлежит: Kureha Corp

In order to provide a compound that shows a strong effect on controlling a plant disease, a triazole compound of the present invention (i) is a compound in which —OH group, —R 2 group, and CH 2 —Ar group are bonded in cis configuration with a cyclopentane, (ii) is (−)-enantiomer or (+) enantiomer, and (iii) is represented by Formula (I): (wherein R 1 represents an alkyl group; R 2 represents a haloalkyl group; and Ar represents a substituted/unsubstituted aromatic hydrocarbon group or a substituted/unsubstituted aromatic heterocyclic group.

Подробнее
10-04-2014 дата публикации

Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors

Номер: US20140100255A1
Принадлежит: GlaxoSmithKline LLC

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation. 1. A method of treatment comprising the administering a compound which is N-{[3 ,5-difluoro-3′-(1H-1 ,2 ,4-triazol-3-yl)-4-biphenylyl]methyl}-2 ,3-dihydro-1H-inden-2-amine or a salt thereof to a human suffering from drug addiction , substance addiction , or a combination thereof.2. The method of wherein said compound is a citrate claim 1 , phosphate or mono- or di-hydrochloride salt of N-{[3 claim 1 ,5-difluoro-3′-(1H-1 claim 1 ,2 claim 1 ,4-triazol-3-yl)-4-biphenylyl]methyl}-2 claim 1 ,3-dihydro-1H-inden-2-amine.3. The method of wherein said compound is the citrate salt.4. The method of wherein said compound is the phosphate salt.5. The method of wherein said compound is the mono- or di-hydrochloride salt.6. A method of treatment comprising the administering a pharmaceutical composition comprising (i) a compound which is N-{[3 claim 2 ,5-difluoro-3′-(1H-1 claim 2 ,2 claim 2 ,4-triazol-3-yl)-4-biphenylyl]methyl}-2 claim 2 ,3-dihydro-1H-inden-2-amine or a salt thereof and (ii) at least one carrier or excipient to a human suffering from drug addiction claim 2 , substance addiction claim 2 , or a combination thereof.7. The method of wherein said compound is a citrate claim 6 , phosphate or mono- or di-hydrochloride salt of N-{[3 claim 6 ,5-difluoro-3′-(1H-1 claim 6 ,2 claim 6 ,4-triazol-3-yl)-4-biphenylyl]methyl}-2 claim 6 ,3-dihydro-1H-inden-2-amine.8. The method of wherein said compound is the citrate salt.9. The method of wherein said compound is the phosphate salt.10. The method of wherein said compound is the mono- or di-hydrochloride salt. This application is filed as a continuation application of U.S. Ser. No. 12/376,580, filed Feb. 6, 2009, which is a National Phase Application of International Application No. PCT/EP2007/075422 filed Aug. 8, 2007, which claims priority from 60/821,845 ...

Подробнее
02-01-2020 дата публикации

Near-ir glucose sensors

Номер: US20200000383A1
Принадлежит: Profusa Inc

Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.

Подробнее
07-01-2016 дата публикации

PROCESS FOR THE PREPARATION OF SUBSTITUTED OXIRANES AND TRIAZOLES

Номер: US20160002189A1
Принадлежит:

The present invention relates to a process for the preparation of the compounds II 119-. (canceled)21: The process of claim 20 , wherein more than 1.5 equivalents to 4 equivalents of water in relation to one equivalent of compound III are used.22: The process of claim 20 , wherein 1.3 to 1.6 equivalents of the trimethylsulfonium methylsulfate IV per 1 equivalent of compound III are used.23: The process of claim 20 , wherein at least 3 equivalents of base per 1 equivalent of compound III are used.24: The process of claim 20 , wherein as reagent IV an aqueous solution of trimethylsulfonium methylsulfate III containing 33 to 37 wt % of trimethylsulfonium kation is used.27: The process of claim 25 , wherein the product resulting from step (ii) or (iia) claim 25 , respectively claim 25 , is crystallized from toluol and/or an aliphatic alcohol.28: The process of claim 27 , wherein the aliphatic alcohol is selected from methanol claim 27 , ethanol claim 27 , n-propanol claim 27 , iso-propanol claim 27 , n-butanol claim 27 , isobutanol or any mixture thereof.29: The process of claim 25 , wherein the base used in step (ii) or (iia) claim 25 , respectively claim 25 , is selected from NaOH claim 25 , KOH claim 25 , NaCOand KCO.30: The process of claim 25 , wherein the base used in step (ii) or (iia) claim 25 , respectively claim 25 , is selected from NaOH and KOH.31: The process of claim 25 , wherein the amount of base used in step (ii) or (iia) claim 25 , respectively claim 25 , is equal to or less than 0.6 equivalents per 1 equivalent of compound II.32: An aqueous solution of trimethylsulfonium methylsulfate IV containing 33 to 37 wt % of trimethylsulfonium kation.33: A use of the aqueous solution of trimethylsulfonium methylsulfate IV according to for the synthesis of an oxirane from the respective oxo compound.34: A crystalline form of 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1 claim 32 ,2 claim 32 ,4-triazol-1-yl)propane-2-ol which claim 32 , in an X-ray ...

Подробнее
05-01-2017 дата публикации

Piperazine derivatives having multimodal activity against pain

Номер: US20170001967A1
Принадлежит: Individual

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Подробнее
04-01-2018 дата публикации

COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Номер: US20180002298A1
Принадлежит:

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia. 2. A method of disrupting or inhibiting the formation claim 1 , deposition claim 1 , accumulation claim 1 , or persistence of tau fibrils and/or aggregates claim 1 , comprising administering a therapeutically effective amount of the compounds of .3. The method of claim 2 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.4. The method of claim 2 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.5. The method of claim 2 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day.6. A method resulting in neuroprotection from a tauopathy in a mammal comprising the step of administrating a therapeutically effective amount of a compound of .7. The method of where the tauopathy is one selected from; Alzheimer's disease claim 6 , Pick's disease claim 6 , progressive supranuclear palsy claim 6 , corticobasal degeneration claim 6 , familial frontotemporal dementia/Parkinsonism linked to chromosome 17 claim 6 , amyotrophic lateral sclerosis/Parkinsonism-dementia complex claim 6 , argyrophilic grain dementia claim 6 , dementia pugilistic claim 6 , diffuse neurofibrillary tangles with calcification claim 6 , progressive subcortical gliosis and tangle only dementia.8. An article of manufacture claim 1 , comprising packaging material claim 1 , the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , contained within packaging material claim 1 , which is used for treating ...

Подробнее
02-01-2020 дата публикации

Photoredox-Catalyzed Direct C-H Functionalization of Arenes

Номер: US20200002284A1
Автор: Nicewicz David
Принадлежит:

The invention generally relates to methods of making substituted arenes via direct C—H amination. More specifically, methods of making para- and ortho-substituted arenes via direct C—H amination are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. 2. The method of claim 1 , wherein the electron donating group is selected from —OH claim 1 , —SH claim 1 , —NH claim 1 , C1-C8 alkyl claim 1 , C1-C8 alkoxy claim 1 , C1-C8 thioalkoxy claim 1 , C1-C8 alkylamino claim 1 , (C1-C8)(C1-C8) dialkylamino claim 1 , —OC(═O)R claim 1 , —NHC(═O)R claim 1 , and Ar;{'sup': 6', '7, 'wherein each of Rand Ris independently selected from C1-C8 alkyl; and'}{'sup': '2', 'wherein Aris selected from aryl and heteroaryl and substituted with 0, 1, 2, or 3 groups independently selected from halogen and C1-C8 alkyl.'}3. The method of claim 1 , wherein Z is F.48-. (canceled)12. (canceled)13. The method of claim 1 , wherein the fluoride is selected from ammonium fluoride claim 1 , cesium fluoride claim 1 , and triethylamine hydrofluoride.1415-. (canceled)16. The method of claim 1 , wherein the oxidant is molecular oxygen.17. The method of claim 1 , wherein the oxidant is 2 claim 1 ,2 claim 1 ,6 claim 1 ,6-tetramethyl-1-piperidinyloxy radical (TEMPO).1820-. (canceled)21. The method of claim 1 , wherein Z is —CN.29. The method of claim 1 , wherein the compound is isotopically-labeled.30. The method of claim 25 , wherein the compound contains a radioactive isotope.31. The method of claim 1 , wherein the compound is not isotopically-labeled. This application is a continuation of U.S. application Ser. No. 15/826,092, filed Nov. 29, 2017, which is a continuation of International Application No. PCT/US2016/035549 with an international filing date of Jun. 2, 2016, which claims priority to U.S. Provisional Application No. 62/170,632 filed on Jun. 3, 2015, the contents of which are incorporated ...

Подробнее
02-01-2020 дата публикации

TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS

Номер: US20200002296A1
Автор: Adam Julia
Принадлежит: MIRONID LIMITED

Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes, are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP) are also described. 112-. (canceled)14. (canceled)16. (canceled)17. The method of wherein the excessive intracellular cyclic AMP signalling is caused by:a. excessive hormone levels produced by an adenoma;b. a gain-of-function gene mutation in a G-protein coupled receptor (GPCR);{'sub': 's', 'c. an activating mutation in the GNAS1 gene, which encodes the α-subunit of the G-protein G; or'}d. a bacterial toxin.18. The method of claim 15 , wherein the disease is cancer.19. The method of claim 18 , wherein the cancer is prostate cancer.20. The method of claim 15 , wherein the disease is:a. pituitary adenoma, Cushing's disease, polycystic kidney disease or polycystic liver disease;b. hyperthyroidism, Jansens's metaphyseal chondrodysplasia, hyperparathyroidism, or familial male-limited precocious puberty;c. McCune-Albright syndrome;d. cholera, whooping cough, anthrax, or tuberculosis;e. HIV, AIDS, or Common Variable Immunodeficiency (CVID);f. melanoma, pancreatic cancer, leukaemia, prostate cancer, adrenocortical tumours, testicular cancer, primary pigmented nodular adrenocortical diseases (PPNAD),or Carney Complex;g. autosomal dominant polycystic kidney disease (ADPKD) or autosomal recessive polycystic kidney disease (ARPKD);h. maturity onset diabetes of young type 5 (MODY5); ori. cardiac hypertrophy.21. The method of claim 20 , wherein the disease is:a. autosomal dominant polycystic kidney disease (ADPKD); orb. autosomal recessive polycystic kidney disease (ARPKD).23. (canceled)24. The method of claim 22 , wherein the disease or disorder is mediated by excessive intracellular cyclic AMP signalling.25. (canceled)26. The method of claim 24 , wherein the abnormal ...

Подробнее
03-01-2019 дата публикации

C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS

Номер: US20190002398A1
Принадлежит:

The present invention is directed to a compound represented by Structural Formula (A): 4. The compound of claim 3 , wherein Ris hydrogen or a (C-C)alkyl.5. The compound of claim 3 , wherein Ris selected from (C-C)alkyl claim 3 , (C-C)cycloalkyl(C-C)alkyl claim 3 , (C-C)alkoxy(C-C)alkyl claim 3 , phenyl claim 3 , phenyl(C-C)alkyl claim 3 , (C-C)cycloalkyl and halo(C-C)alkyl claim 3 , wherein each alkyl claim 3 , alkoxy and cycloalkyl moiety in the groups represented by Ris optionally substituted with one or more substituents independently selected from the group consisting of (C-C)alkyl and halo; and each phenyl moiety in the groups represented by Ris optionally substituted with one or more substituents independently selected from the group consisting of (C-C)alkyl claim 3 , halo claim 3 , (C-C)alkoxy claim 3 , (C-C)alkoxy(C-C)alkyl claim 3 , —CN claim 3 , halo(C-C)alkyl claim 3 , and halo(C-C)alkoxy.6. The compound of any one of claim 3 , wherein Ris selected from hydrogen claim 3 , methyl and ethyl.7. The compound of claim 6 , wherein Ris selected from the group consisting of cyclopropyl claim 6 , cyclobutyl claim 6 , cyclopentyl claim 6 , cyclopropylmethyl claim 6 , cyclobutylmethyl claim 6 , phenyl claim 6 , benzyl claim 6 , —(CH)—O—CH claim 6 , —(CH)—OCH claim 6 , —C(CH) claim 6 , —CH(CH) claim 6 , —CHC(CH) claim 6 , —CHCH(CH) claim 6 , —CH—CF claim 6 , —(CH)—CHF claim 6 , and —(CH)CH; n is 0 claim 6 , 1 claim 6 , 2 claim 6 , 3 claim 6 , 4 claim 6 , 5 or 6; and wherein the phenyl or benzyl group represented by Ris optionally substituted with one or two substituents independently selected from the group consisting of (C-C)alkyl claim 6 , halogen claim 6 , (C-C)alkoxy claim 6 , (C-C)alkoxy(C-C)alkyl claim 6 , —CN claim 6 , halo(C-C)alkyl claim 6 , and halo(C-C)alkoxy.8. The compound of claim 7 , wherein Ris selected from cyclopropyl claim 7 , cyclopropylmethyl claim 7 , cyclobutyl claim 7 , cyclopentyl claim 7 , cyclohexyl claim 7 , —(CH)—O—CH claim 7 , —C(CH) ...

Подробнее
07-01-2021 дата публикации

SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS

Номер: US20210002261A1
Принадлежит:

The present disclosure relates to compounds of Formula (I): 2. The compound of any one of the preceding claims , wherein Ris C-Cbicyclic cycloalkyl.6. The compound of any one of the preceding claims , wherein Ris C-Ctricyclic cycloalkyl.9. The compound of any one of the preceding claims , wherein , Ris C-Caryl optionally substituted by one or more R.10. The compound of any one of the preceding claims , wherein Ris phenyl is substituted by one , two , or three R.15. The compound of any one of the preceding claims , wherein Ris cyclopentyl , cyclohexyl , or cycloheptyl , wherein the cyclopentyl , cyclohexyl , or cycloheptyl is optionally substituted by one or more R.17. The compound of any one of the preceding claims , wherein at least one Ris methyl , ethyl , isopropyl , isobutyl , secbutyl , methoxy , ethoxy , —CF , —OCF , —OCHCF , F , or Cl.18. The compound of any one of the preceding claims , wherein Ris —R.19. The compound of any one of the preceding claims , wherein Ris —(CXX)—R.20. The compound of any one of the preceding claims , wherein Ris —(CXX)—R.21. The compound of any one of the preceding claims , wherein each Xis H.22. In some embodiments , at least one Xis C-Calkyl , C-Calkenyl , or C-Calkynyl , wherein the C-Calkyl , C-Calkenyl , or C-Calkynyl is optionally substituted with one or more halo , —CN , —OH , —O(C-Calkyl) , —NH , —NH(C-Calkyl) , —N(C-Calkyl) , or oxo.23. The compound of any one of the preceding claims , wherein Ris 4- to 8-membered heterocycloalkyl optionally substituted with one or more C-Calkyl , C-Calkenyl , C-Calkynyl , C-Chaloalkyl , halo , —CN , —OH , —O(C-Calkyl) , —NH , —NH(C-Calkyl) , —N(C-Calkyl) , or oxo.24. The compound of any one of the preceding claims , wherein Ris 4- to 8-membered heterocycloalkyl.25. The compound of any one of the preceding claims , wherein Ris 5- to 8-membered heterocycloalkyl.26. The compound of any one of the preceding claims , wherein Ris 5- to 7-membered heterocycloalkyl.27. The compound of any one of ...

Подробнее
13-01-2022 дата публикации

1-PHENYL-2-PHENYLETHANE DERIVATIVE

Номер: US20220009869A1
Принадлежит: KAO CORPORATION

Provided is a novel compound having a selective activating effect on ERβ. The present invention provides a compound represented by the following formula (1) wherein Rrepresents a cycloalkyl group having 3 to 8 carbon atoms, an alkenyl group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 5-membered nitrogen-containing heteroaryl group, a 4- to 6-membered cyclic amino group, an alkanoylamino group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 1-trifluoromethyl-1-hydroxymethyl group, or a 1-methylpropyl group; Rto Rare the same or different and each represent a hydrogen atom or a fluorine atom; and Rrepresents a hydrogen atom or an alkanoyl group having 2 to 5 carbon atoms, or a salt thereof. 2: An ERβ activating agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.3: A skin aging preventing or ameliorating agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.4: A sebum secretion inhibiting agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.5: An acne preventing or ameliorating agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.6: A hot flash preventing or ameliorating agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.7: A prostatic hyperplasia preventing or ameliorating agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.8: An androgen activation inhibiting agent comprising the compound represented by the formula (1) or the salt thereof according to as an active ingredient.932-. (canceled) The present invention relates to a compound having high selectivity for estrogen receptor 0.Estrogen, also called follicle hormone ...

Подробнее
20-01-2022 дата публикации

ARYLAZOLE COMPOUND AND PEST CONTROL AGENT

Номер: US20220017472A1
Принадлежит: NIPPON SODA CO., LTD.

A compound represented by Formula (I), or a salt or N-oxide compound thereof is provided. 3. A pest control agent comprising at least one compound according to claim 1 , a salt thereof claim 1 , or an N-oxide compound thereof as an active ingredient and a carrier.4. A method for controlling a pest or mite on or in a subject comprising the step of administrating to the subject an effective amount of at least one compound according to claim 1 , a salt thereof claim 1 , or an N-oxide compound thereof claim 1 ,{'i': 'Polyphaga', 'wherein the pest or mite is one or more selected from the group consisting of: butterflies and moths of the order Lepidoptera; pests of the order Thysanoptera; pests of the order Hemiptera; pests of the order ; pests of the order Diptera; pests of the order Orthoptera; and mites of the subclass Acari.'}5. A method for controlling an insect or acarus on or in a subject comprising the step of administrating to the subject an effective amount of at least one compound according to claim 1 , a salt thereof claim 1 , or an N-oxide compound thereof.6. A method for controlling an ectoparasite on or in a subject comprising the step of administrating to the subject an effective amount of at least one compound according to claim 1 , a salt thereof claim 1 , or an N-oxide compound thereof.7. A method for controlling or expelling an endoparasite in a subject comprising the step of administrating to the subject an effective amount of at least one compound according to claim 1 , a salt thereof claim 1 , or an N-oxide compound thereof. This application is a Divisional of U.S. application Ser. No. 16/061,783, which is the U.S. National Stage application of PCT/JP2016/087358, filed Dec. 15, 2016, which claims priority from Japanese Patent Application No. 2015-245712, filed on Dec. 16, 2015, Japanese Patent Application No. 2016-060605, filed on Mar. 24, 2016, and Japanese Patent Application No. 2016-198677, filed on Oct. 7, 2016, the contents of which are ...

Подробнее
09-01-2020 дата публикации

Triazole derivatives, intermediates thereof and their use as fungicides

Номер: US20200008427A1
Принадлежит: Bayer CropScience AG

The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Подробнее
27-01-2022 дата публикации

Chimeric small molecules for the recruitment of antibodies to cancer cells

Номер: US20220023428A1
Принадлежит: YALE UNIVERSITY

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Подробнее
10-01-2019 дата публикации

Nuclear transport modulators and uses thereof

Номер: US20190008833A1
Принадлежит: Biogen MA Inc

and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Подробнее
14-01-2016 дата публикации

METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX

Номер: US20160009664A1
Принадлежит: Molecular Insight Pharmaceuticals

The present invention b directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. 2. The ligand of claim 1 , wherein X is —(CH)— and m is 2.3. The ligand of claim 1 , wherein X is —O— and m is 4.4. The ligand of claim 1 , wherein Rand Rare each independently substituted or unsubstituted carboxy(C-C)alkylene claim 1 , Ris substituted or unsubstituted carboxy(C-C)alkylene.5. The ligand of claim 1 , wherein Rand Rare each independently claim 1 , —CHCOOH claim 1 , and Ris —C(CHCHCOOH).6. The ligand of claim 1 , wherein G and G′ are —(CH(R))—R— claim 1 , and Ris NRR claim 1 , or —COH.7. The ligand of claim 1 , wherein each of Rand Ris —C(CHCHCOOH.8. The ligand of claim 1 , wherein the compound is an inhibitor of carbonic anhydrase-IX.11. The metal complex of claim 10 , wherein M is Tc claim 10 , Re claim 10 , or Re.13. The metal complex of claim 12 , wherein M is Tc claim 12 , Re claim 12 , or Re.15. The ligand of in which the ICvalue is lower by a factor of at least 10.16. The ligand of in which the ICvalue is lower by a factor of at least 100.17. The ligand of in which the ICvalue is lower by a factor of at least 200.18. The ligand of in which the ICvalue is lower by a factor from 2 to about 200. This application is a continuation of application Ser. No. 13/734,534. filed Jan. 4, 2013 which claims the benefit of the priority date of U.S. Provisional Application No. 61/584,146, filed Jan. 6, 2012, the complete disclosure of which is incorporated herein by reference in its entirely.The present technology relates generally to the field of radiopharmaceuticals and their use in nuclear medicine for the treatment of various disease states. It is well known that tumors may express unique proteins associated with their malignant phenotype or may over-express normal constituent proteins as compared to the expression of these proteins in normal cells. The expression of distinct proteins on the surface of tumor ...

Подробнее
14-01-2016 дата публикации

PROCESS FOR PREPARATION OF 4-(1-(4-(PERFLUOROETHOXY)PHENYL)-1H-1,2,4-TRIAZOL-3-YL)BENZOYL AZIDE

Номер: US20160009665A1
Принадлежит: DOW AGROSCIENCES LLC

By either forming a triaryl acid halide or a triaryl mixed anhydride and subsequently treating with aqueous sodium azide, triaryl acyl azides are prepared in high yield using inexpensive reagents in a process in which by-products are easily removed from the triaryl acyl azide. 3. The process of or in which Ris OCFCF.4. The process of in which Ris CHCH.5. The process of in which the inorganic acid halide halogenating agent is thionyl chloride.6. The process of in which the organic solvent that is inert to the halogenating agent is a chlorinated hydrocarbon.7. The process of in which the organic solvent that is inert to sodium azide and the triaryl acid chloride is miscible with water.8. The process of in which the organic solvent that is inert to sodium azide and the triaryl acid chloride is an ether claim 7 , a nitrile claim 7 , a ketone or an alcohol.9. The process of in which the organic solvent that is inert to sodium azide and the triaryl acid chloride is immiscible with water and a phase transfer catalyst is employed.10. The process of in which the organic solvent that is inert to sodium azide and the triaryl acid chloride is a hydrocarbon or a chlorinated hydrocarbon.11. The process of in which the phase transfer catalyst is a tetraalkylammonium chloride claim 9 , bromide or hydrogen sulfate .12. The process of in which the base is an alkali metal carbonate claim 2 , a tertiary amine or an aromatic amine.13. The process of in which the organic solvent that is inert to the chlorocarbonate is miscible with water.14. The process of in which the organic solvent that is inert to the chlorocarbonate is an ether claim 13 , a nitrile or a ketone.15. The process of in which the organic solvent that is inert to sodium azide is miscible with water.16. The process of in which the organic solvent that is inert to sodium azide is an ether claim 15 , a nitrile claim 15 , a ketone or an alcohol.17. The process of in which the organic solvent that is inert to sodium azide is ...

Подробнее